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Risk Reduction Decision Making in Women with BRCA1/2 Gene Mutations 
 
Heidi M. King 
 
ABSTRACT 
 
With technological advances in testing for gene mutations, a new population of 
BRCA1/2 women is becoming aware of their increased risk for developing breast and/or 
ovarian cancer.  A salient issue these women face is which risk-reducing option to 
choose.  Little is known about the decision making factors underlying the choice of 
prophylactic mastectomy for women with a BRCA1/2 mutation.  To address this issue, 
137 unaffected, positive BRCA1/2 gene mutation carriers (42 who opted for prophylactic 
mastectomy, 95 who did not) served as participants.  All women completed an on-line 
battery that assessed the following theory-based decision making variables:  advantages 
and disadvantages of prophylactic mastectomy (normative decision theory), physician 
recommendation (shared decision making theory), cancer worry (affect theory), and 
information-seeking coping style.  With the exception of information-seeking style  
(p = .8715), the decision making variables of advantages and disadvantages of 
prophylactic mastectomy, physician input, and cancer worry did have a significant 
relationship with risk-reduction option chosen. Women who rated the advantages higher 
than the disadvantages of prophylactic mastectomy (r = .31, p < .001), whose physician 
had recommended prophylactic mastectomy exclusively (Χ2 = 11.85; p < .001), and who 
reported higher cancer worry scores a month after receiving BRCA1/2 positive results  
vii 
(r = .28, p < .001) were more likely to have chosen prophylactic mastectomy.  The 
perceived impact (conflict, regret, cancer worry, and general well-being) of risk-reducing 
option selected was also explored. The direction of these relationships indicates that 
having chosen prophylactic mastectomy was associated with less decisional conflict  
(r = -.38, p < .0001), decisional regret (r = -.58, p < .0001), depressive symptomatology 
(r = -.19, p < .05), and cancer worry (r = -.39, p < .0001).  The results suggest higher 
assessments of advantages over disadvantages of prophylactic mastectomy, doctor 
recommendation for prophylactic mastectomy exclusively, and higher cancer worry at 
time of testing is associated with choosing the risk-reducing option of prophylactic 
mastectomy.  In addition, women who chose prophylactic mastectomy fared better 
psychologically than those who did not.  Continued research addressing decision making 
variables and the impact of risk-reducing decisions may lead to improved understanding 
on how best to approach these difficult decisions. 
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Chapter One 
 
Introduction 
            Due to technological advances in testing for gene mutations, a new population of 
women is becoming aware of their increased risk for developing breast and/or ovarian 
cancer.  While this yet undiagnosed population is referred to as unaffected in the 
medical community, these women have a unique set of medical and psychological needs.  
The term pre-vivors was coined on the Facing Our Risk of Cancer Empowered, Inc. 
(FORCE; www.facingourrisk.org) message board to describe this population of 
individuals.  FORCE is a non-profit organization created specifically to attend to the 
issues arising in carriers of the Breast Cancer 1 and Breast Cancer 2 (BRCA1/2) gene 
mutations which were discovered in 1994 (Miki et al.) and 1995 (Wooster et al.), 
respectively.  Approximately, 1 out of every 345 and 1out of 1000 people in the general 
population in the United States are BRAC1/2 gene mutation carriers (Whittemore, Gong, 
& Itnyre, 1997; Rubin, 2003).  For certain populations this rate is even higher.  For 
example, people with Ashkenazi Jewish heritage, 1 out of every 40 people is estimated to 
be BRCA1/2 carrier (Robles-Diaz, Goldfrank, Kauff, Robson, & Offitt, 2004).  The most 
salient issue for women who are carriers of the BRCA1 and/or BRCA2 gene mutations is 
the increased risk of developing breast and/or ovarian cancer in their lifetimes.  
Specifically, BRCA1 carriers have a 65% chance (95% confidence interval 44%-78%) 
and BRCA2 carriers have a 45% chance (95% confidence interval 31%-56%) of being 
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diagnosed with breast cancer by age 70.  Ovarian cancer incidence rates are slightly 
lower with 39% (95% confidence interval 18%-54%) of BRCA1 carriers and 11% (95% 
confidence interval 2.4%-19%) of BRCA2 carriers (Antoniou et al., 2003).  Since testing 
is considered appropriate for individuals with at least a 5% estimated chance of being a 
BRCA1/2 gene mutation carrier (Armstrong, et al., 2000), a growing number of women 
are faced with a series of medical decisions.  Should she undergo genetic counseling?  
Should she be tested and find out her BRCA1/2 test results?  With whom, if anyone, 
should she share the test results?  Which type of risk-reducing strategy should she 
pursuesurveillance, prophylactic surgery/surgeries, and/or chemoprevention?  Each 
decision comes with its own set of advantages and disadvantages.  Because of the 
difficulty involved in making these decisions, it is imperative that researchers, medical 
providers, and patients understand the factors that go into the decision making process, as 
well as the subsequent impact of these decisions (Schwartz, Peshkin, Tercyak, Taylor, & 
Valdimarsdottir, 2005).  This study will focus on the decision making factors underlying 
the choice of a risk-reducing strategy for women at increased risk for developing breast 
cancer due to the presence of a BRCA1/2 mutation.  Specifically, the primary aim of this 
study is to explore the relationship between four different theory-driven predictors (e.g., 
advantages and disadvantages of risk-reducing strategies, doctor recommendation, cancer 
worry, and information-seeking style) and the decision to undergo prophylactic 
mastectomy in unaffected carriers of a BRCA1/2 gene mutation.  The secondary aim is to 
explore how choice of risk-reducing strategy impacts these women through decisional 
conflict, decisional regret, current cancer worry, and depressive symptomatology.   
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First, a brief background on the motivation for undergoing, and the ambiguity 
surrounding, genetic testing will be provided.  Then, an overview of risk-reducing 
strategies for breast cancer (surveillance, prophylactic mastectomy, and 
chemoprevention) currently available to BRCA1/2 gene mutation carriers will be 
reviewed.  These topics are followed by a discussion of four decision making theories 
that will provide a conceptual framework for studying risk-reducing decision making in 
this new population of women:  a) normative decision theory, b) shared decision making 
theory, c) affect-based theory, and d) informational style theory.  Finally, a review of 
literature on the impact of risk-reducing strategy choice, such as decisional regret and 
conflict, in this population will be provided. 
Reasons for Pursuing Genetic Testing 
             Prior research suggests that people have four main reasons for obtaining genetic 
counseling and BRCA1/2 testing (Pasacreta, 2003).  The most popular reason has to do 
with wanting the information in order to determine their childs risk of inheriting the gene 
(Lerman, Daly, Masny, & Balshem, 1994; Struewing, Lerman, Kase, Giambaressi, & 
Tucker, 1995; Bluman et al., 1999; Lerman et al., 1997; Meijers-Heijboer et al., 2000).  
Another factor motivating testing is to seek an answer to uncertainty about future risk of 
developing cancer (Chaliki et al. 1995; Struewing et al., 1995; Bluman et al., 1999; 
Lerman et al., 1997; Jacobsen, Valdimarsdottir, Brown, & Offit, 1997).  A third 
motivating factor for testing is to obtain information to inform decisions about which 
risk-reducing strategy to pursue.  With a 45-65% increased risk of developing breast 
cancer (Antoniou et al., 2003) and an 11-39% increased risk of developing ovarian cancer 
in their lifetimes (Antoniou et al., 2003; Lerman et al., 1994; Chaliki et al., 1995; 
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Struewing et al., 1995; Bluman et al., 1999; Lerman et al., 1997; Jacobsen et al., 1997), 
many BRCA1/2 carriers are motivated to find ways to limit mortality from breast and/or 
ovarian cancer.  Finally, people have reported pursuing BRCA1/2 testing in order to make 
informed decisions about marriage and/or childbearing (Lerman et al., 1994; Struewing et 
al., 1995; Bluman et al., 1999; Lerman et al., 1997; Jacobsen et al., 1997). 
Ambiguity of Test Results 
The results of testing for BRCA1/2 gene mutations typically reflect ambiguity.  
Unlike genetic testing for Huntingtons Disease, which almost always yields conclusive 
results, testing for BRCA1 and BRCA2 may be less informative since sensitivity and 
specificity of BRCA1/2 mutation testing is high.  The genetic test for BRCA1/2 has the 
following three potential results:  1) true positive, 2) true negative, or 3) inconclusive 
negative.  If a woman receives a positive result, she has a 45-65% chance of developing 
breast and/or 11-39% ovarian cancer in her lifetime (Antoniou et al., 2003).   Therefore, 
not all people with a BRCA1/2 gene mutation will go on to be diagnosed with cancer.  
Conversely, those without a gene mutation (a true negative result) may still develop 
sporadic breast or ovarian cancer in their lifetime.   Finally, an inconclusive negative 
result may occur for several different reasons.  A woman from a family in which no 
family member has been tested for the gene mutation may have an as yet unknown gene 
mutation that is not BRCA1/2 (Baum, Friedman, & Zakowski, 1997; Prasacreta, 2003), or 
she may have a variant in BRCA1/2 that cannot be detected by the sequencing method 
currently employed (Peshkin, DeMarco, Brogan, Lerman, & Isaacs, 2001).  Therefore, all 
three test results have varying levels of ambiguity with regard to whether or not a woman 
will develop breast cancer.  These varying levels may cause women with positive test 
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results to make decisions about future risk-reducing strategies differently from women 
with true negative or inconclusive negative results.  Therefore, the scope of this study 
will be limited to a homogeneous sample of women who have received positive BRCA1/2 
genetic test results. 
Risk-Reducing Strategies 
            The risk-reducing strategies available to BRCA1/2 gene mutation carriers and 
other women at high risk for breast cancer include the following:  surveillance, 
prophylactic mastectomy, and chemoprevention.  The following section will summarize 
the medical findings of these three strategies.  Specifically, the sensitivity and specificity 
of surveillance methods, the risk reduction rates for prophylactic mastectomy, and the 
known results from chemoprevention studies will be reviewed. 
Surveillance for Breast Cancer 
The American Cancer Society Guidelines for Breast Cancer Screening (Smith et 
al., 2003) suggest the following screening guidelines for women at average risk for breast 
cancer:  clinical breast exams every three years starting in their twenties and thirties and 
annually for healthy women starting in their forties, the option to learn and conduct breast 
self-exams, and mammography starting at age 40.  For women at increased risk of breast 
cancer, the American Cancer Society vaguely suggests modifications to the 
recommendations above including earlier initiation of all screenings, shorter intervals 
between screenings, and additional strategies like magnetic resonance imaging (MRI) and 
ultrasound.  Without sufficient evidence, they suggest that women decide on a course of 
screening action via shared decision making with their doctors. 
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The U.S. Preventive Services Task Force (USPSTF; 
www.ahrq.gov/clinic/usptf/uspsbrgen.htm) only recommends mammography every one 
to two years for women over 40.  They neither recommend for or against regular clinical 
breast exams or breast self-exams.  For women who are carriers of the BRCA1/2 
mutation, USPSTF recommends a discussion between patient and doctor about the 
potential risks and benefits of chemoprevention. There is no conclusive research on how 
women at increased risk for breast cancer should screen for the disease.   
Observational studies have been conducted to examine the sensitivity and 
specificity of surveillance for breast cancer in women with an increased risk for breast 
cancer.  One study is a non-randomized observational study of a BRCA1/2 mutation 
cohort.  Brekelmans et al. (2001) followed 1,198 women with elevated risk for 
developing breast cancer.  These women were divided into three groups based on their 
risk status.  The first group consisted of BRCA1/2 gene mutation carriers (n = 128).  The 
second group was categorized as high-risk (n = 621) because they had three or more first 
or second-degree relatives with breast cancer diagnosed at an early age (< 50 years of 
age).  The third group of women was categorized as moderate-risk (n = 449) because they 
had more than two relatives with breast cancer.  The research protocol involved 
instructions for monthly breast self-exams, clinical breast exams every 6 months, yearly 
mammography, and MRI starting in 1995 for either gene mutation carriers or women 
with dense breast tissue.  After a mean follow-up of three years, the sensitivity of the 
screening for gene mutation carriers was substantially less (56%) than for the overall 
sensitivity of the screening program for high-risk women (74%).  The small sample size 
of gene mutation carriers is a limitation, so conclusions must be made cautiously.  
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However, results suggest that current surveillance methods may be less effective for 
BRCA1/2 gene mutation carriers than other women at high or moderate risk.   
Kuhl et al. (2005) conducted a surveillance cohort study with a sample of 529 
women (n = 43 BRCA1/2 gene mutation carriers) with mixed levels of elevated risk for 
contracting breast cancer, as well as with mixed cancer histories.  The aim of this study 
was to compare surveillance accuracies of the following methods:  clinical breast exams, 
mammography, breast ultrasound, and MRI.  Each participant received semiannual 
clinical breast exams and breast ultrasounds along with an annual mammography and 
MRI.  During the course of the study, 43 cases of breast cancer were diagnosed.  Of 
those, eight were diagnosed in mutation carriers.  For women who were BRCA1/2 gene 
mutation carriers, the sensitivity of MRI was 100% (versus 91% for the sample as a 
whole) and the sensitivity of mammography was 25% (versus 33% for the sample as a 
whole).  The specificities were similar on all four imaging modalities for the gene 
mutation carriers and the group as a whole.  This study suggests that MRI allows for 
earlier detection of breast cancer among women with BRCA1/2 gene mutations. 
Warner et al. (2004) conducted a similar study comparing the specificity and 
sensitivity of the four surveillance options (clinical breast exam, mammography, 
ultrasound, and MRI) among women with BRCA1/2 mutations (n = 236) who did (39%) 
or did not (60%) have a history of breast cancer.  Each participant received all four 
modalities each year, for one to three years.  The following modalities are ranked in order 
from highest to lowest in sensitivity:  MRI (77%), mammography (36%), ultrasound 
(33%), and clinical breast exam (9.1%).  Specificity ranged from 95.4% (MRI) to 99.8% 
(mammography).  It was suggested that, for MRI to become part of standard care for 
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carriers of the BRCA1/2 gene mutations will require further research on mortality rates, 
the ideal timing of this surveillance method, continued studies on the specificity of this 
method, and the effectiveness of the MRI when conducted outside of a controlled 
research setting (Robson & Offit, 2004). 
In addition to the limitations cited in the Warner et al. (2004) study, additional 
gaps in the literature on the surveillance options for unaffected BRCA1/2 gene mutation 
carriers exist (Calderon-Margalit & Paltiel, 2004).  These include heterogeneity of study 
samples that include gene mutation carriers with or without a previous cancer diagnosis 
as well as women at varying levels of high risk (Kuhl et al., 2005; Kuhl et al., 2000; 
Brekelmans et al., 2001) and the lack of important outcome measures, including mortality 
rates (Warner et al., 2004), grade and stage at diagnosis, and psychological well-being 
(Kuhl et al. 2005; Kuhl et al., 2000; Brekalmans et al., 2001). 
             The advantages and disadvantages of choosing surveillance are not clear-cut.  The 
non-invasiveness of surveillance is a definite advantage.  While surveillance is the least 
invasive risk- reducing strategy, there may be some temporary psychological distress as a 
result of inevitable false-positive test results (Lampic, Thurfjell, Bergh, & Sjödén, 2001; 
Steggles, Lightfoot, & Sellick, 1998; Fentiman, 1998; Gilbert et al., 1998; Lowe, 
Balanda, Del Mar, & Hawes, 1999).  While there is promise that MRI may increase the 
potential for early detection (Kuhl et al., 2000; Warner et al., 2004; Stoutjesdijk et al., 
2001; Tilanus-Linthorst, Obdeijn, Bartels, de Koning, & Oudkerk, 2000), it does nothing 
to reduce the incidence of breast cancer.  No studies could be found that looked at 
surveillance in relation to breast cancer mortality, stage and grade, or quality of life 
(Calderon-Maergalit & Paltiel, 2004).   
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Prophylactic Mastectomy 
Prophylactic mastectomy, or the removal of healthy breast tissue, can be done in 
various wayssubcutaneous mastectomy (removal of both breasts while keeping 
overlying skin and nipple), total simple mastectomy (removal of both breasts and 
overlying skin without axillary dissections), modified radical mastectomy (removal of 
both breasts with overlying skin and axillary contents), and radical mastectomy (removal 
of both breasts with overlying skin, pectoralis muscles, and axillary contents).  
Regardless of the type of mastectomy performed, no form of mastectomy can completely 
eliminate all of the breast tissue, and therefore no form can completely eliminate the risk 
of breast cancer (Lostumbo, Carbine, Wallece, & Ezzo, 2005). 
Several studies yielded similar findings with regard to the reduction of breast 
cancer rates in women at high risk who opt for prophylactic surgery.  Hartmann et al. 
(1999) conducted a retrospective study of 214 women categorized as high-risk who had 
opted for prophylactic mastectomy between 1960 and 1993.  They were followed for a 
median time frame of 14 years.  Their untreated sisters (n = 403) served as the control 
group.  A 90% risk reduction was found for the high-risk group with only three women 
who had opted for prophylactic surgery being diagnosed with breast cancer compared to 
156 of their untreated sisters. 
Hartmann et al. (2001) conducted a follow-up study in which they obtained blood 
samples from their original sample of high-risk women.  Twenty-six BRCA1/2 gene 
mutation carriers were detected in the high-risk group.  Of these women who had opted 
for prophylactic surgery, none had developed breast cancer after 13.4 years of follow-up.  
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Statistically, six to nine of these 26 women should have developed breast cancer 
suggesting a risk reduction of 89.5% as in the original study.   
Rebbeck et al. (2004) reported a similar risk reduction rate.  In this prospective 
study, 105 BRCA1/2 gene mutation carriers who opted for prophylactic mastectomy 
alone, or in conjunction with prophylactic oophorectomy (i.e., the surgical removal of 
healthy ovaries in an attempt to prevent ovarian cancer), were matched on age, gene, and 
place of treatment with 378 BRCA1/2 gene mutation carriers who did not opt for 
prophylactic surgery of any kind.  The groups were followed for 5.5 years and 6.7 years, 
respectively.  At the end of the follow-up period, two women from the surgery group and 
184 women from the non-surgery group had been diagnosed with breast cancer.  This 
represents a 95% reduction rate for women who had concurrent oophorectomy and a 90% 
reduction rate for women who did not have a concurrent oophorectomy relative to the 
non-surgery group. 
              While these studies suggest high rates of risk reduction for prophylactic 
mastectomy, there remain some limitations to consider (Eisen, 1999).  The Hartmann et 
al. (1999, 2001) studies were made up of heterogeneous samples, with women of varying 
degrees of risk being compared to one another.  Through blood samples drawn from the 
majority of the women at a later time (Hartmann et al., 2001), they found that 
approximately 15% (26/176) of the women in the high-risk group were BRCA1/2 gene 
carriers.  Therefore, approximately 85% of the sample was presumably not at the 45-65% 
increased risk for hereditary breast cancer.  While some lives were saved by use of 
prophylactic mastectomy (Hartmann et al., 1999; Rebbeck et al., 2004), hundreds of 
women may have undergone surgery unnecessarily.  Finally, self-selection bias may be a 
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problem with these studies, especially if baseline risk differs between surgical and 
nonsurgical groups (Klaren, vant Veer, van Leeuwen, & Rookus, 2003; Calderon-
Margalit & Paltiel, 2004). 
Chemoprevention and Breast Cancer 
            Chemoprevention, or the use of medication as a risk-reducing strategy for cancer, 
is currently being studied in BRCA1/2 gene mutation carriers.  Tamoxifen, one of the 
most studied medications, is already an established adjuvant treatment option for women 
diagnosed with cancer (Heuson, 1976; Margreiter & Wiegele, 1984).  It is either 
prescribed alone or along with chemotherapy and has been shown to reduce the risk of a 
future, secondary cancer diagnosis in the unaffected breast (Rutqvist et al., 1991; Fisher 
& Redmond, 1991).   
In the Breast Cancer Prevention Trial (BCPT; Fisher et al., 1998), 13,338 women 
at high risk for cancer were randomized into a tamoxifen group or a placebo group for 
five years.  For the purposes of this study, high-risk was defined by one of the following 
three criteria:  1) age over 60 years, 2) age between 35 and 59 years with a greater than 
1.66% risk of cancer as predicted by the Gail model, or 3) a history of lobular carcinoma 
in situ (i.e., benign change in the cells of the milk duct that suggest an increased risk for 
breast cancer in the future).  Results of the study suggest that tamoxifen reduces the 
occurrences of both invasive and noninvasive breast cancer.  Specifically, this medication 
reduced the risk of invasive cancer by 49% (p < .01) and noninvasive cancer by 50% (p < 
.01).  At the time the study was conducted, blood samples were taken from each 
participant in order to be assessed for BRCA1/2 gene mutations in the future.  However, 
results from those blood samples suggest a low number of actual BRCA1/2 gene mutation 
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carriers in this study.  King et al. (2001) studied the 288 women who had been diagnosed 
with breast cancer while participating in the BCPT.  Of this sample, 6.6% were BRCA1/2 
gene mutation carriers.  Results suggest that tamoxifen reduced breast cancer incidence in 
women with BRCA2, but the results were not clear for BRCA1.  The sample size was too 
small to make any generalizations.  Further research is needed in the area of 
chemoprevention for breast cancer in BRCA1/2 gene mutation carriers.   
Decision Making Theories 
             What factors predict risk-reducing decisions for BRCA1/2 carriers?  In a review of 
decision making factors by Schwartz, Peshkin, et al. (2005), risk reduction rates alone did 
not predict risk-reducing strategy.  If that were the case, the majority of women would 
pursue prophylactic mastectomy because of its 90% risk reduction rate compared to a 0% 
risk-reduction for surveillance (Rebbeck et al., 2004, Hartmann et al., 1999, 2001) and an 
unknown reduction rate for chemoprevention (Fisher et al., 1998; King et al., 2001).  
However, in three risk-reducing decision studies with BRCA1/2 gene mutation carriers 
conducted in the U.S., only 3% of women had opted for mastectomies at one year 
(Lerman et al., 2000; Peshkin et al., 2002) and none of the women had opted for 
mastectomies at two years post-genetic testing (Botkin et al., 2003).   Therefore, in 
looking beyond the numbers, it will be important to consider other factors that may go 
into the selection of risk-reducing strategies.  This study will focus on the following 
theory-based predictors in the selection of mastectomy or no mastectomy in this 
population:  1) analysis of advantages and disadvantages, 2) doctor recommendation,  
3) affect, and 4) information-seeking style.   
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Normative Decision Theory 
            Normative decision theory suggests that individuals decisions are made by a 
logical, unbiased, measured assessment of the advantages and disadvantages surrounding 
a choice.  This theory is exemplified by the traditional model of genetic counseling.  
Cancer genetic counseling typically consists of an unbiased, nondirective relaying of 
information over three sessions.  In the first session, pretest information is gathered, 
advantages and disadvantages of testing are presented, and the nature of the test and its 
results are explained.  Patients are then asked to make a decision about testing.  If they 
decide to test, there is a second meeting where a DNA sample is obtained.  Finally, 
during the third session, test results are provided (Schwartz, Peshkin, et al., 2005).  It is 
believed that if comprehensive and accurate information is provided during genetic 
counseling, the patient will utilize this information in combination with their personal 
preferences to arrive at a personally satisfactory decision about whether or not to engage 
in genetic mutation testing.  The preferred outcome is then an informed decision that 
reflects a persons preferences.  This theory can be extrapolated to involve decisions that 
people make about risk-reducing strategies following genetic testing.   
            The following two studies exemplify the normative decision making theory as 
applied to genetic counseling.  Armstrong et al. (2000) retrospectively studied 211 
women from the University of Pennsylvania Breast and Ovarian Risk Evaluation 
Program (BCREP).  The BCREP is a university-based, multidisciplinary program in 
Philadelphia designed to provide women with individualized breast cancer risk 
assessment, as well as the option to pursue genetic counseling and testing. These women 
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were categorized into the following two groups based on gene mutation testing:  those 
who had undergone BRCA1/2 testing (n = 125) and those who decided against testing  
(n = 86).  As predicted by the normative decision theory, women who ranked the 
beneficial factors for genetic testing significantly higher were more likely to undergo 
genetic testing.  These beneficial factors included information for family members (p < 
.01), learning about cancer risk (p = .01), as well as help in decision making about both 
prophylactic mastectomy (p = .01) and prophylactic oophorectomy (p < .01).  
Conversely, women who rated negative effects of testing, such as insurance (p  = .04) or 
job discrimination (p = .01) significantly higher were less likely to undergo genetic 
testing. 
            Lerman et al. (1996) conducted a prospective study that used principles from 
normative decision theory.  This was accomplished by use of a base measure of decision 
making predictors for genetic testing.  Information about 192 participants at high risk for 
the BRCA1 mutation was collected via telephone interviews conducted  one to two 
months prior to testing.  As expected, participants who reported more benefits of genetic 
testing at baseline were significantly more likely to get tested. 
            The principles of the normative decision theory have also been applied to the 
study of choice of risk-reducing strategies.  Because of a lack of studies looking 
specifically at the advantages and disadvantages of prophylactic mastectomy among 
BRCA1/2 gene mutation carriers, a study looking at oophorectomy decision making is 
reviewed.  In a cross-sectional, retrospective study, a group of high-risk women (n = 30) 
who had opted for prophylactic oophorectomy between 1-5 years previously were 
matched to high-risk women who had opted for surveillance (n = 28) during the same 
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time frame (Fry, Rush, Busby-Earle, & Cull, 2001).  They were all assessed as to how 
they rated the advantages and disadvantages of oophorectomy.  Women in the surgical 
group rated the following decision making factors significantly higher  
(p < .05) than women in the surveillance group:  the desire to reduce cancer worry, desire 
to reduce the risk of ovarian cancer, and worries about the effectiveness of ovarian 
screening.  This study exemplifies the normative decision theory, with differing ratings of 
advantages and disadvantages predicting surgical group membership.   
Shared Model of Decision Making 
The shared decision model is an outgrowth of the normative decision theory.  It 
incorporates the view that patients are consumers of medical care and both desire and 
have a right to actively participate in decision making concerning treatment and risk-
reducing strategies.  Although the definition, timing, and purpose of the shared decision 
model is not universally agreed upon (McNutt, 2004), a broad definition typically 
involves comprehensive education on the risks and benefits that are part of the normative 
decision making theory.  In addition, it includes an active attempt to engage patient 
values in the decision making process.  This is often accomplished via decision aids such 
as brochures, videos, computer software, as well as physician input.  Therefore, in this 
model, effective decision making is conceptualized as providing the patient with both 
objective medical information incorporated with his/her subjective values and opinions 
about the trade-offs that need to be made (Coulter, 2002).   
Before reviewing if women at-risk for breast cancer incorporate their physicians 
opinion into their decisions to get genetic testing or pursue surgery as a risk-reducing 
strategy, the following studies review the opinions of health care providers regarding 
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these decisions. One hundred sixty-three genetic counselors from the National Society of 
Genetic Counselors Special Interest Group in Cancer were surveyed through the mail.  
They were asked if they would personally undergo genetic testing if they were found to 
be at 50% risk for carrying the BRCA1/2 mutations (Matloff et al., 2000).  They were 
further asked what risk-reducing strategy they would pursue if they were 35 years of age, 
had completed their families, and were found to be a carrier.  Eighty-five percent of 
counselors stated they would pursue genetic testing with a 50% risk.  They cited reasons 
for choosing testing that were consistent with those of actual women in this situation who 
opted for testing (Lerman et al., 1994; Chaliki et al., 1995; Struewing et al., 1995; 
Bluman et al., 1999; Lerman et al., 1997; Jacobsen et al., 1997; Meijers-Heijboer et al., 
2000).  Eight percent of the genetic counselors stated they would decline testing because 
of fear of discrimination and knowing this information would not alter plans for current 
medical management.  With regard to risk-reducing strategies, a majority of the sample 
(68%) stated they would pursue oophorectomy while 25% stated they would pursue 
mastectomy.  These results are higher than actual BRCA1/2 carriers reports of their 
intentions (17% for mastectomy and 33% for oophorectomy) reported by Lerman et al. 
(1996).  However, they are consistent with other studies of doctors in this field (Geller et 
al., 1998; O'Malley, Klabunde, McKinley, & Newman, 1997).  Stefanek (1995) surveyed 
female radiation and medical oncologists on the course of risk-reducing strategy they 
would choose if they had a known 35-40% chance of breast cancer risk.  In this sample, 
50% of the radiologists and 86% of the medical oncologists stated they would opt for 
prophylactic bilateral mastectomy. 
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While no studies could be found that directly looked at the relationship between 
physician opinion and prophylactic mastectomy in BRCA1/2 gene mutation carriers, 
studies looking at physician opinion of genetic testing and treatment outcome in women 
for varying risk of breast cancer were identified.  Based on the findings from these 
studies, one may extrapolate the way in which physician opinion may influence a 
BRCA1/2 gene mutation carriers decision to pursue prophylactic mastectomy.   
Women with extensive family histories for breast cancer are potential candidates 
for the shared decision model at two different points.  The first decision point involves 
whether or not a woman should pursue genetic testing.  Armstrong et al. (2002) 
conducted a retrospective study with 335 women involved in the University of 
Pennsylvania Breast and Ovarian Risk Evaluation Program (BCREP).  As discussed 
earlier, the BCREP is a multidisciplinary program designed to provide women with 
individualized breast cancer risk assessment, genetic counseling, and genetic testing.  
After making the decision whether or not to undergo genetic testing, each woman 
received a packet in the mail asking her to retrospectively state if she would have liked to 
have known the opinion of her primary care doctor and the opinion of her BCREP doctor 
(yes, no, or unsure).  This approach is a challenge to the traditional, non-directive 
approach typically offered in genetic counseling because it brings in the opinions of the 
physician.  In the sample as a whole, 33% pursued BRCA1/2 testing while 67% did not.  
A majority of the women in this study (77%) wanted to know the opinions of the BCREP 
doctors.  In addition, forty-nine percent wanted to know the opinions of their primary 
care doctors.  Women who chose not to be tested were more likely to have wanted the 
opinions of their doctors.  This study suggests that all the needs of women undergoing 
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gene mutation testing may not be met by the traditional approach to genetic counseling.  
The retrospective nature of this study is an obvious limitation, as well as the inability to 
generalize from the data because of the homogeneous sample of white, highly educated 
women that participated in this program.  
Schwartz, Lerman, et al.s prospective study (2005) of the utilization of BRCA1/2 
mutation testing in women newly diagnosed with breast cancer supports findings from 
Armstrong et al.s (2002) study.  Specifically, 211 women completed a structured phone 
interview assessing basic sociodemographic variables, psychological variables, medical 
variables, as well as whether or not their oncologist recommended BRCA1/2 mutation 
testing.  Then, they underwent a traditional, nondirective genetic counseling session, 
testing, and feedback sessions as desired.  Results of a logistic regression model 
suggested that doctor recommendation was a contributing factor in determining whether 
or not women pursued genetic mutation testing.  Patients who received a doctors 
recommendation were three times more likely to pursue genetic testing.  Though not part 
of the nondirective genetic counseling model, doctor recommendation emerged as a 
deciding factor.  The findings from these two studies on preference to know doctor 
recommendation for genetic testing suggest the possibility that preference for doctor 
recommendation will also be true when choosing a risk-reducing strategy such as 
prophylactic mastectomy. 
Van Roosmalen et al. (2004b) tested the shared decision model in an intervention 
study with 88 women who had undergone free BRCA1/2 genetic testing.  Half of the 
group was randomized to receive a shared decision model intervention, while the other 
half of the sample received usual care.  The intervention consisted of three sessions with 
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a counselor over three weeks with decisional aides.  Health states following treatment 
options were written on laminated cards.  Patients rank-ordered these cards and then 
discussed the value of each of the health states using time as a unit of comparison.  
Outcome variables included treatment choice, decision related outcomes such as strength 
of treatment preference, decision uncertainty, perceived participation in decision making, 
weighing treatment choice, perceived preference of the specialists, and support and 
advice from specialists, as well as well-being.  Although there was no effect on 
preventive treatment choices between the groups, women in the intervention group 
reported significantly stronger preferences (p = .02) and a stronger belief that they had 
weighed the advantages and disadvantages more effectively (p = .01).  Women in the 
intervention group also felt that their specialists had a preference for one breast treatment 
over another (p < .01).  While not significant (p = .09), women in the intervention group 
did report a desire for more support and advice about treatment choices for breast cancer 
from their specialists. The results suggest women who were given the chance to 
participate more fully in the decision making process felt that their specialists had an 
opinion about their treatment and were interested in their specialists support and advice 
to a higher degree than those who did not partake in the decision making process as 
much.   In addition to these treatment and decision outcomes, there were significant long-
term effects on well-being.  Women in the intervention group reported less intrusive 
thoughts (p = .05) and better general health (p = .01). 
Van Roosmalen et al.s (2004b) study on shared decision making adds to the 
current literature by broadening the scope of treatment outcomes addressed; specifically, 
patient well-being (as measured by intrusive thoughts and general health) and decision 
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related outcomes (such as strength of treatment preference, decision uncertainty, 
perceived participation in the decision making, and weighting of treatment choice).  
These issues were addressed in addition to preventive treatment choice alone.  
Limitations of this study included the time and labor intensiveness of the intervention 
evaluated.  While the above review suggests the desire for physician input about genetic 
testing and treatment choices, there is a need in the literature to address how physician 
input specifically relates to choice of prophylactic mastectomy in women who are 
BRCA1/2 carriers.   
Affect-Based Decision Making 
As shown above, women at varying risks for breast and ovarian cancers appear to 
be making decisions by weighing the advantages and disadvantages of risk-reducing 
options, as well as doctor recommendation.  In addition, several studies have shown that 
cancer-specific distress may be an important factor in making decisions about genetic 
testing, as well as risk-reducing strategies.  Specifically, cancer-related anxiety or fears 
appear to be a motivating factor for women to pursue testing or risk-reducing options 
more aggressively.  The affect heuristic (Slovic, Finucane, Peter, & MacGregor, 2004; 
Ubel & Lowenstein, 1997, Schwartz, Peshkin, et al., 2005) may be a potential 
explanation for this phenomenon.  This theory posits that people making decisions under 
duress will rely more on how they feel affectively than on other decisional factors.   
While no studies that looked directly at the relationship of affect in BRCA1/2 gene 
mutation carriers to pursuit of prophylactic mastectomy could be found, a review will be 
provided of studies using at-risk women with the following treatment outcomes:  decision 
to undergo genetic testing and intentions to pursue mastectomy.  Based the findings from 
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these studies, one may extrapolate the way in which affect may influence BRCA1/2 gene 
mutation carriers decisions to pursue prophylactic mastectomy.   
The first study to be reviewed examined cancer-specific distress as a predictor for 
pursuit of BRCA1 testing.  The study involved 149 women and men with hereditary 
breast ovarian cancer (HBOC) syndrome, or multiple family members in multiple 
generations with early onset of breast and/or ovarian cancers (Lerman et al., 1997).  
Blood samples had been collected from most of the participants, years previously, in an 
effort to isolate the BRCA1 gene (Feuntaun et al., 1993).  These participants were 
contacted for the present study with notification that their test results were being made 
available.  If they decided to participate, they would undergo a 40-minute phone 
interview, an education session, and if desired, receive their BRCA1 results at a disclosure 
session. Baseline measures of general distress (Center for Epidemiologic Studies 
Depression Scale--CES-D; Radloff, 1977) and breast-cancer specific distress (Intrusion 
Subscale of the Impact of Events ScaleIES; Horowitz, Wilner, & Alvarez, 1979) were 
administered.  Fifty-eight percent of the participants requested testing results, while 42% 
declined their results. In a hierarchical logistic regression analysis, cancer-specific 
distress was entered after sociodemographic variables and objective risk and was found to 
significantly improve prediction of receipt of BRCA1 test results (p < .05).   People with 
higher cancer-related distress scores were more likely to obtain their test results.  
 Van Dijk et al. (2003) looked at the relation of breast cancer worry to intentions to pursue 
prophylactic mastectomy in women at risk for familial breast cancer.  As part of a larger 
study, a mixed sample of affected and unaffected women with varying rates of risk (n = 
241) completed a questionnaire including two items from Lerman et al.s (1991) Cancer 
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Worry Scale (CWS) both before and after a genetic counseling session in which their 
familial lifetime cancer risk was revealed.  Higher levels of breast cancer worry at pre-
counseling independently predicted intention to pursue prophylactic mastectomy (β = 
0.32; p < .01), while objective risk information did not (p = .78). 
In the following hypothetical, vignette study looking at decision factors, women 
with a first degree relative diagnosed with breast cancer (n = 129) were compared to 
women without a first degree relative with breast cancer (n = 104) (Stefanek, Enger, 
Benkendorf, Flamm Honig, & Lerman, 1999).  Each participant read a vignette about a 
woman diagnosed with breast cancer and was asked to answer questions on whether she 
would choose prophylactic mastectomy or close screening given this fictitious womans 
history.  Women who reported higher levels of breast cancer worry (measured by one 
item) were more likely (p < .05) to voice an interest in prophylactic mastectomy. 
Information Style Theory 
             Miller, Roussi, Caputo, and Kruss (1995) have identified two main information-
seeking styles, monitoring and blunting, that relate to the way that individuals under 
stress apply information.  For example, a medical patient who incorporates a monitoring 
style seeks out, focuses on, and amplifies threatening cues about her medical situation.  
She is attuned to the negative, dangerous, or painful portions of her illness.  Conversely, a 
medical patient with a blunting style avoids, minimizes, and actively distracts herself 
from any threatening information, symptoms, or cues.   
             The following two studies focus on information-seeking style and genetic 
counseling decisions for women at high risk for breast and/or ovarian cancer.  Before 
genetic testing for the BRCA1/2 gene mutation was available, Lerman et al. (1994) 
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conducted a cross-sectional study with 121 first-degree relatives of ovarian cancer 
patients with no personal cancer history.  The aims of this study were to assess factors 
that were related to intentions to test, along with expectations about the anticipated 
impact of such testing.  The Miller Behavioral Style Scale (MBSS; Miller, 1987) was 
used to study information-seeking style.  A majority of women (75%) expressed interest 
in testing.  As expected, being a woman who employed a monitoring coping style was 
positively associated with an anticipated negative impact of testing.  Specifically, 
monitors expected more of the negative consequences of testing including depression, 
anxiety, and decreased quality of life.   
            Schwartz, Lerman, Miller, Daly, and Masny (1995) studied 103 unaffected first-
degree relatives of women with ovarian cancer assessed via a phone interview and self-
report questionnaires, including the MBSS.  As predicted in this study, being a woman 
with a monitoring coping style was positively related to higher perceived risk, intrusive 
thoughts, and psychological risk.  In addition, high monitors overestimated their risk for 
ovarian cancer regardless of their actual risk.   
No studies to date could be found looking at the role that this monitoring-blunting 
information-seeking style plays in actual choice of risk-reduction strategies by BRCA1/2 
carriers.  However, given the findings of overestimation of risk (Schwartz et al., 1995) 
and psychological risk (Lerman et al., 1994; Schwartz et al., 1995) reported in genetic 
testing with this population, high monitoring women may be more likely to opt for 
prophylactic mastectomy. 
Gaps in the Literature 
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The studies reviewed above have demonstrated that assessment of advantages and 
disadvantages, physician opinion, affect, and information-seeking appear to influence 
decisions made by women at increased risk for breast cancer.  However, limitations exist 
in the current literature on predictors of decision making about prophylactic mastectomy 
for women who have tested positive for the BRCA1/2 gene mutations.  Specifically, the 
samples reviewed are heterogeneous.  They have included women with varied risk levels 
(Van Dijk et al., 2003; Stefanek et al., 1999) and women with varied cancer histories 
(Van Dijk et al., 2003).  In addition, the studies reviewed for the most part have not 
investigated risk-reducing strategy decisions in general, or prophylactic mastectomy 
decisions in particular.  Finally, the studies reviewed have failed to look at the predictive 
value of the four variables of assessment of advantages and disadvantages, physician 
opinion, affect, and information styles simultaneously.   
Perceived Impact of Risk-Reducing Choice 
The second aim of this study focuses on the perceived impact of risk-reducing 
choice.  Connolly and Reb (2005) identified some overarching, definitional features of 
the construct of regret.  Specifically, regret involves both a cognitive and affective 
evaluation of two or more choices.  Though an aversive feeling, it differs from 
disappointment or general negative affect.  For the purpose of this study, the focus of the 
potential regret will be the type of risk-reducing alternative chosen (i.e., mastectomy or 
no mastectomy). 
No studies could be found that compared decisional regret, decisional satisfaction, 
or decisional conflict among women with BRCA1/2 gene mutations who chose 
prophylactic mastectomies versus women who opted for surveillance (Lostumbo et al., 
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2005).  However, a few studies have looked at decisional regret or satisfaction among 
women with unknown mutational status who have chosen prophylactic mastectomy.  
Borgen et al. (1998) looked at regret in a sample of 370 women who had undergone 
bilateral mastectomies between 1945 and 1996 and who signed up to be part of the 
National Prophylactic Mastectomy Registry.  Five percent of the women (n = 21) 
reported regret with approximately half of these women (n = 10) stating they would not 
have chosen surgery again.  The discussion initiator of surgery (physician versus patient) 
was the only statistically significant variable (p < .05) that distinguished women who had 
regrets from those who did not.  Specifically, more women whose physicians initiated 
conversations about surgery (19/255) had regrets versus women who initiated 
conversations about surgery themselves (2/108).  Overall, however, the majority of 
women (n = 349) did not express regret over undergoing prophylactic mastectomies. 
One study (Stefanek, Helzlsouer, Wilcox, & Houn, 1995) assessed the satisfaction 
level of 14 women with a family history of breast cancer who opted for prophylactic 
mastectomy in the past 6-30 months (M = 9.4).  Satisfaction in the following areas were 
assessed by a 5-point Likert scale:  recovery time physically and emotionally, degree of 
discomfort and expectation of discomfort, support system as it pertained to their decision, 
overall satisfaction with decision, reconstruction, and proclivity to recommend to a 
friend.  Satisfaction was high in all areas with the exception of reconstruction.   This 
study will examine decisional regret and conflict in women who are BRCA1/2 gene 
mutation carriers.  
26 
Aims 
The current study has two aims.  The first aim is to explore the relationship 
between a set of theory-driven decision making variables and the actual treatment 
decisions made by a group of healthy, unaffected women who have tested positive for a 
BRCA1/2 gene mutation.  Because the ideal treatment for carriers of the BRCA1/2 gene 
mutation is yet unknown (Marchetti et al., 2004), women are forced to make their 
decisions on factors other than strict medical information.  The four variables addressed 
are the advantages and disadvantages of prophylactic mastectomy (normative decision 
theory), doctor recommendation (shared decision making theory), cancer worry (affect 
theory), and information-seeking coping style.  For purposes of analysis, the type of 
treatment chosen is classified as whether or not prophylactic mastectomy was performed.  
The second aim is to explore the perceived impact (conflict, regret, cancer worry, 
and general well-being) of the treatment option selected.  The study will look at the 
relationship of decisional conflict, decisional regret, cancer worry, and depressive 
symptomatology in relation to the treatment options women selected. 
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Decision Making Hypotheses 
 The first hypothesis posits that the way in which individuals assess the pros and cons of 
prophylactic mastectomy will be related to the type of treatment chosen.   
1.  Women who rate the pros of prophylactic surgery greater than the cons of 
prophylactic surgery will be more likely to have chosen surgery.  
Conversely, women who rate the cons of surgery greater than the pros of 
surgery will be more likely to have not chosen surgery. 
 
The second hypothesis posits that the treatment chosen will be related to 
recommendation of that treatment by a physician.   
2.  If a physician had recommended prophylactic mastectomy, women will have 
been more likely to have chosen prophylactic mastectomy.  
 
The third hypothesis posits that levels of cancer worry will be related to the type 
of treatment chosen.   
3.  Women with higher levels of reported cancer worry at the time of genetic 
testing will be more likely to have chosen prophylactic mastectomy than 
women with lower levels of reported cancer worry at the time of genetic 
testing. 
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The fourth hypothesis posits that information-seeking style will be related to 
treatment choice.   
4.  Women with greater tendencies to use a monitoring information-seeking style 
will be more likely to have chosen prophylactic surgery.  
 
Depending on results of these hypotheses testing, exploratory analyses will be 
undertaken to examine which variable(s) accounts for the most variance in the treatment 
decision.  Specifically, the analyses will seek to identify which variable(s) from the four 
decision making models provide(s) the best fit for predicting treatment choice in 
BRCA1/2 positive, healthy, unaffected women. 
 
Perceived Impact Hypotheses 
 The fifth set of hypotheses explores the perceived impact of treatment choice.   
5A.  Women who chose prophylactic surgery will experience less decisional 
conflict than women who have not chosen prophylactic surgery. 
5B.  Women who chose prophylactic surgery will experience less decisional 
regret than women who have not chosen prophylactic surgery. 
5C.  Women who chose prophylactic surgery will experience lower levels of 
depressive symptomatology than women who have not chosen prophylactic 
surgery.  
5D.  Women who chose prophylactic mastectomy will experience lower levels of 
cancer worry than women who have not chosen prophylactic mastectomy. 
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Chapter Two 
 
Method 
 
Participants 
          Women without a history of cancer who had tested positive for gene mutations in 
BRCA1/2 were solicited via the website for Facing Our Risk of Cancer Empowered, Inc. 
(FORCE; www.facingourrisk.org).  FORCE is a non-profit organization designed to 
educate, support, raise awareness, and promote research in the area of genetic 
susceptibility for breast and ovarian cancers.  Demographic data made available about 
new FORCE website subscribers between June and August of 2006 (approximately 420 
people) suggest that the majority of subscribers are women between the ages of 36 and 60 
(97%), Caucasian (89%), with no personal history of cancer (57%).  Of the women with 
no personal history of cancer, 25% reported having had genetic testing.   
           Between December 2006 and June 2007, a link to this studys on-line survey was 
advertised on the FORCE website message board, as well as via website pop-ups.  In 
addition, five e-mail reminders about the study were distributed to individuals who 
subscribe to the FORCE newsletter. 
             In order to be considered eligible for the study, participants had to be women at 
least one year post genetic testing.  By surveying women at least one year post-testing, 
we wanted to allow for a reasonable amount of time for these women to make and act on 
decisions regarding risk-reducing options.  In addition to being tested and receiving their 
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positive genetic test results at least one year prior to completing the survey, these women 
also met the following eligibility criteria:  1) be at least 18 years of age, 2) be proficient 
in English, 3) have not undergone oophorectomy as a risk-reducing cancer strategy,  
4) have not received chemoprevention as a risk-reducing strategy, and 5) have no 
personal history of cancer (with the exception of basal cell carcinoma).  
Procedure 
The survey was initially piloted on two women who met study criteria.  The 
executive director of FORCE selected pilot participants.  The purpose of piloting was to 
verify the estimated survey completion time and ensure that the questions were clearly 
worded and fully understood.  Eligible pilot participants were contacted by phone.  A 
scripted format (Appendix A) was followed on the telephone in order to describe the pilot 
study, ask questions to confirm pilot study eligibility, and obtain verbal informed 
consent.  Upon receiving verbal consent, each participant was mailed the following 
materials:  two copies of written informed consent (Appendix B), the survey web address, 
and a self-addressed stamped envelope.  Each woman was asked to return one signed 
copy of the informed consent and provide three potential times that they would be 
available by phone after completing the survey.  Upon receipt of the informed consent, 
the participants were contacted by phone and debriefed.  Using the Question Appraisal 
System (QAS99; Center for Disease Control and Prevention, 1999), each item and set of 
instructions that was not part of standardized measures was reviewed.  The QAS99 
systematically assesses each item in all of the following areas:  instructions, clarity, 
assumptions, knowledge/memory, sensitivity/bias, response categories, and 
miscellaneous problems.  After collecting pilot data, minor changes including the 
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addition of one question and the clarification in the instructions for a section regarding 
attitudes about breast self-examination were made.  One supplementary question was 
added about cosmetic surgery.  In addition to inquiring if women underwent cosmetic 
surgery, a question was added about the specific kind of cosmetic surgery (e.g., 
reconstruction after prophylactic mastectomy, reduction, or augmentation).  In addition, 
the instructions in front of five questions regarding attitudes about breast self-
examination were modified  
After the survey had been successfully piloted, interested parties were then able to 
click onto a secure link embedded into the FORCE website to complete the on-line 
survey.  The first screen described the nature of the study and asked a series of questions 
evaluating eligibility criteria (Appendix C).  If eligibility criteria were not met, 
individuals were directed to a screen thanking them for their interest but informing them 
that they were not eligible for the study.  If eligibility criteria were met, a page with all 
the information relevant to provide informed consent was provided (Appendix D).  Per 
IRB regulations for web-based studies, women provided their consent by clicking on an 
I agree button.  If eligibility criteria were met and consent provided, individuals were 
then able to proceed through the battery of measures (Appendices E-M).  All data was 
housed on a secure server.  
 It was anticipated that substantially more women who volunteered to participate 
would not have undergone prophylactic mastectomy.  After extensive recruitment efforts, 
usable data were collected on 137 eligible women.  As anticipated, more surveys were 
received from women who had not undergone prophylactic mastectomy (95 who did not 
opt for prophylactic and 42 who did opt for prophylactic mastectomy).  Because these 
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two groups did not differ statistically by age (p = .53) or time since genetic testing (p = 
.77), this entire sample of eligible participants (N  = 137) was used in the analyses rather 
than the proposed matching procedure that would have reduced the total sample size to 
84 (42 in each group).  
Measures 
The on-line survey battery assessed demographic and clinical information, 
perceived advantages and disadvantages of prophylactic mastectomy, and physician 
recommendations regarding risk-reducing option.  In addition, valid and reliable 
measures of cancer worry, information-seeking style, decisional conflict, decisional 
regret, and depressive symptomatology were included.  The battery took approximately 
25 minutes to complete. 
Demographic and Clinical Information.  A standardized self-report measure was 
used to obtain demographic and clinical information (Appendix E).  The following 
demographic information was obtained from all participants:  age, race, ethnicity, 
income, educational level, and marital status.  The clinical information collected included 
menopausal status, height and weight, family history of breast and ovarian cancers, time 
since genetic testing, current perceived breast cancer risk, and intentions to undergo an 
oophorectomy.  In addition, information was collected as to whether or not these women 
chose to share their positive genetic results with their primary care doctors.  Time since 
surgery and perceived breast cancer risk prior to prophylactic mastectomy was also 
collected from women who had undergone prophylactic mastectomy.   In addition to 
intentions to undergo prophylactic mastectomy in the future, information on surveillance 
behavior history and future surveillance behavior intentions was gathered from the group 
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who had not opted for prophylactic mastectomy.  Specifically, we collected information 
on if and how often they performed breast self-exams and underwent clinical breast 
exams, mammography, and MRI for the detection of breast cancer. 
Decisional Balance Scale for Prophylactic Mastectomy.  The Decisional Balance 
Scale for Prophylactic Mastectomy (Appendix F) assessed the perceived advantages and 
disadvantages of undergoing prophylactic mastectomy.  The scale was specifically 
designed for this study and consists of 8 items (4 worded as advantages or pros, 4 
worded as disadvantages or cons).  Items for this measure were taken from the 
literature on the assessment of advantages and disadvantages of prophylactic mastectomy 
by women at increased risk for breast cancer (Claes et al., 2005).  Women were asked to 
state the degree to which they had considered these items when deciding whether or not 
to undergo prophylactic mastectomy.  Responses were provided on a 5-point Likert scale 
ranging from strongly agree to strongly disagree.  Coeffecient alphas calculated in 
the present study were .48 for the advantages scale and .44 for the disadvantages scale.  
Physician Input.  Participants answered questions as to whether or not one or 
more doctors made recommendations to them about which risk-reducing strategy they 
should pursue (Appendix G).  They were also asked to state the recommendation(s) 
made. 
Cancer Worry.  The Cancer Worry Scale (CWS; Lerman et al., 1991; Lerman, 
Kash, & Stefanek, 1994) is a 4-item scale measuring the degree to which worrying about 
breast cancer hinders daily functioning (Appendix H-I).  Participants rate each item on a 
4-point Likert scale from not at all or rarely to a lot.   In several studies looking at 
womens worries and concerns about breast cancer, the CWS is recognized as having 
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good internal consistency and test-retest reliability (Bowen et al., 2003; Rees, Fry, Cull, 
& Sutton, 2004).   Women in this study were asked to complete this measure both 
retrospectively (Appendix I; one month after receipt of BRCA1/2 results) as well as for 
the past month (Appendix H). Coefficient alphas were .84 for current reports and .87 for 
retrospective reports of cancer worry.  
Decisional Conflict.  The Decisional Conflict Scale (DCS; OConnor, 1995) is a 
16-item measure designed to assess uncertainty experienced by a person about an 
undertaking (Appendix J).  Participants rate each item on a 5-point Likert scale ranging 
from strongly agree to strongly disagree.  Scores are summed and transformed to 
yield a total score ranging from 0 (no decisional conflict) to 100 (extremely high 
decisional conflict). The validity and reliability of the DCS has been demonstrated in 
prior research (OConnor, 1995; Song & Sereika, 2006; University of Ottawa, 2006 ). 
Coefficient alpha for the total score in the present study was .94.  
Decisional Regret.  The Decision Regret Scale (OConnor et al., 1998) is a 5-item 
measure designed to assess the degree of remorse or distress over a past decision 
(Appendix K).  Participants rate each item on a 5-point Likert scale ranging from 1 
strongly agree to 5 strongly disagree.  Scores are summed and transformed to yield a 
total score ranging from 0 to 100.  The validity and reliability of the Decision Regret 
Scale has been demonstrated in prior research (Brehaut et al., 2003; University of 
Ottowa, 1996).  Coefficient alpha in the current study was .91.  
Depressive Symptomatology.  The Center for Epidemiologic Studies, Depression 
Scale (CES-D; Radloff, 1977) is a 20-item self-report measure developed to assess 
current depressive symptomatology (Appendix L).  Items are rated on a 4-point Likert 
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scale ranging from 0 (rarely or none of the time) to 3 (most or all of the time).  
Participants are asked to respond to each item based on the degree to which they have 
been experiencing each symptom in the past week.  Total scores range from 0 to 60, with 
higher scores indicating more severe depressive symptomatology.  The validity and 
reliability of the CES-D has been demonstrated in numerous studies (Devins, Orme, 
Costello, & Binik, 1988; Hann, Winter, & Jacobsen, 1999; Weissman, Prusoff, & 
Newberry, 1975). Coefficient alpha in the current study was .93.   
Information-Seeking Style.  The Miller Behavioral Style Scale (MBSS; Miller, 
1987) measures differences in the way individuals either seek out (i.e., monitor) or avoid 
(i.e., blunt) information relevant to threatening situations (Appendix M).   The scale is 
composed of four stressful situations (e.g., dentist appointment, hostage situation, 
airplane ride during a steep dive, and the possibility of being laid off at work) followed 
by eight statements that reflect different reactions in each situation.   Each set of eight 
statements is evenly divided into monitoring and blunting reactions.  Coefficient alphas 
for the monitoring scale range from .75 to.79 and .67 to .69 for the blunting scale (Miller, 
1987).  The coefficient alphas for the present study were .78 for the monitoring scale and 
.62 for the blunting scale.  Because the monitoring scale has been proven to be a better 
predictor of health behaviors (Miller et al., 1988), only the monitoring scale was used in 
subsequent analyses.   
 
36 
 
 
 
 
 
Chapter Three 
 
Results 
 
Preliminary Analyses 
Participants Who Opted for Prophylactic Mastectomy.  Of the 192 women who 
completed the on-line survey, 56 women (29%) reported having undergone prophylactic 
mastectomies (see Figure 1).  Of these women, 14 (25%) were found to be ineligible for 
the following reasons: genetic testing done within the past year (n = 8), duplicate survey 
entries (n = 3), report of both ovaries having been removed without a hysterectomy (n = 
1), mastectomy prior to genetic testing (n = 1), and survey malfunction resulting in 
missing data (n = 1).  The mean age of the remaining 42 women was 36 years (SD = 8.07, 
range = 19-55).  The majority was Caucasian (93%), not of Ashkenazi Jewish heritage 
(57%), married (71%), had a college degree or higher education (81%), and had an 
annual household income greater than or equal to $40,000 (76%) (see Table 1).  On 
average, these women underwent prophylactic mastectomy 14 months prior to 
participating in the study (M = 14.48; SD = 14.50) with time since prophylactic 
mastectomy ranging for 0 to 58 months.  The time that elapsed between genetic testing 
and undergoing prophylactic mastectomy ranged from 1 month to 76 months (M = 18.69; 
SD = 21.24). 
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Figure 1. Flowchart of Recruitment 
  
192 Surveys Received 
136 Non- 
Prophylactic 
Mastectomy 
Surveys 
56 Prophylactic 
Mastectomy 
Surveys 
41 Ineligible Surveys 
 
!31  Less than one year  since 
genetic testing 
 
! 7  Duplicate surveys 
 
! 2  Chemoprevention drugs 
 
! 1  Ovaries removed w/o 
hysterectomy 
95 Eligible 
Non-Prophylactic 
Mastectomy 
Surveys 
14 Ineligible Surveys 
 
! 8 Less than one year since 
genetic testing 
 
! 3  Duplicate surveys 
 
! 1 Survey malfunction 
 
! 1   Ovaries removed w/o 
hysterectomy 
 
! 1   Mastectomy prior to 
testing 
42 Eligible 
Prophylactic 
Mastectomy 
Surveys 
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Table 1 
Demographic Characteristics of Participants Who Had Opted for Prophylactic 
Mastectomy versus Participants Who Had Not Opted for Prophylactic Mastectomy  
 
           Participants who Opted for      Participants who Did Not Opt for 
 Prophylactic Mastectomy  Prophylactic Mastectomy                        
  
 N (%) N (%)            X2          p 
 
Ashkenazi Jewish 2.14 .14 
  
 Yes 18 (43%) 27 (28%) 
 No 24 (57%) 68 (72%) 
 
 
Race .91 .34 
  
 White 39 (93%) 93 (98%) 
 Non-White  3  (7%)  2  (2%) 
 
 
Marital Status 1.72 .18 
 
 Married 30 (71%) 55 (58%) 
 Not Married 12 (29%) 40 (42%) 
 
 
Education  .00 .97 
 
 < Partial College  8 (19%) 20 (21%) 
 > College Grad 34 (81%) 75 (79%) 
 
 
Household Income  .02 .89 
 
 < $40, 000   5 (12%)  9  (9%) 
 > $40, 000 32 (76%) 75 (79%) 
 Did not answer  5 (12%) 11 (12%) 
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Participants Who Did Not Opt for Prophylactic Mastectomy.  Of the 192 women 
who completed on-line surveys, 136 women (71%) reported not having undergone 
prophylactic mastectomies (see Figure 1).  Of these women, 41 were found to be 
ineligible for the following reasons:  genetic testing done within the past year (n = 31), 
duplicate survey entries (n = 7), use of chemoprevention drugs (n = 2), and report of both 
ovaries having been removed without a hysterectomy (n = 1).  The mean age of the 
remaining 95 women was 35 years (SD = 8.84, range = 21-65).  The majority was 
Caucasian (98%), not of Ashkenazi Jewish heritage (72%), married (58%), had a college 
degree or higher education (79%), and had an annual household income greater than or 
equal to $40, 000 (79%) (see Table 1).   
Women who did not opt for prophylactic mastectomy were asked about their 
breast cancer surveillance behaviors.  The majority of these women reported the 
following breast cancer surveillance behaviors at least once in the past year: breast exam 
conducted by a medical professional (96%), mammogram (78%), and MRI (61%) (see 
Table 2).  Regarding breast self-exams, 72% reported performing self-exams in the past 
month with 64% reporting regular self-exams in the past year (about one per month or  
more than one per month) (see Table 3).  Eighty percent reported intentions to perform 
regular self-exams in the upcoming year (about one per month or more than one per 
month).  Even with these high rates, only 23% of women expressed feeling either very 
confident or extremely confident in personal performance of breast self-exams.  
Twenty percent of these women reported plans (either likely or extremely likely) to 
have a prophylactic mastectomy in the next 6 months (see Table 3). 
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Table 2 
Surveillance Behaviors of Participants Who Had Not Opted for Prophylactic Mastectomy  
 
                                                                      N                                      (%) 
 
Breast Exam Conducted by Medical Professional in Past Year 
 
 Yes   91   (96%) 
 No    4    (4%) 
 
Breast Exam Conducted by Medical Professional in Past Three Years 
 
 0    1    (1%) 
 1  6  (6%) 
 2  7  (8%) 
 3 24 (25%) 
 4 57 (60%) 
 
Mammograms in Past Year 
 
 Yes   74   (78%) 
 No   21   (22%) 
 
Mammograms in Past Three Years 
 
 0   16   (17%) 
 1 14 (15%) 
 2 20 (21%) 
 3 33 (35%) 
 4 12 (12%) 
 
MRI in Past Year 
 
 Yes   58   (61%) 
 No   37   (39%) 
 
MRI in Past Three Years 
 
 0   35   (37%) 
 1 27 (28%) 
 2 14 (15%) 
 3 13 (14%) 
 4  6  (6%) 
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Table 3 
Medical Characteristics of Participants Who Had Not Opted for Prophylactic 
Mastectomy  
 
                                                                       N                                     (%) 
 
Plan to have Prophylactic Mastectomy in the next 6 Months 
 
 Extremely Unlikely 52 (55%) 
 Unlikely 13 (13%) 
 Not Sure 11 (12%) 
 Likely  8  (8%) 
 Extremely Likely 11 (12%) 
 
 
Self Breast Exam in Past Month 
  
 Yes   68   (72%) 
 No   27   (28%) 
 
 
Self Breast Exam in Past Year 
  
 Not al all   9   (10%) 
 Less than 1/month  25   (26%) 
 About 1/month   40   (42%) 
 More than 1/month  21   (22%) 
 
Intentions to perform Self Breast Exam in Next Year 
 
 Not al all    6    (6%) 
 Less than 1/month  13   (14%) 
 About 1/month   56   (59%) 
 More than 1/month  20   (21%) 
 
  
Personal Confidence in Performing Self Breast Exam 
 
 Not at all 17 (18%) 
 Little confident 21 (22%) 
 Fairly confident 35 (37%) 
 Very confident 17 (18%) 
 Extremely confident  5  (5%) 
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T-tests or chi-square analyses were conducted, as appropriate, to compare the 
participants who had opted for prophylactic mastectomy (n = 42) with the participants 
who had not opted for prophylactic mastectomy (n = 95) on demographic variables.   The 
groups did not differ significantly on age (t = -.62, p = .53).  On the demographic 
variables of race, Ashkenazi Jewish heritage, marital status, education, and household 
income, results revealed not even a marginally significant difference (p < .1) between the 
groups (see Table 1).  Therefore, none of these variables were included is covariates in 
the subsequent analyses. 
            T-tests or chi-square analyses were also conducted to compare the groups on 
medical variables.  The groups did not differ significantly on menopausal status (!2 = 
1.82, p = .18), body mass index (t = .17, p = .86), time since genetic testing (t = -.03, p = 
.77), or whether or not they disclosed their positive genetic test results with their 
physicians (!2 = .29, p = .59).  Regarding family history of first degree relatives with 
breast or ovarian cancers, the groups did not differ on whether or not they had first degree 
relatives with breast cancer (!2 = .59, p = .44), but did differ significantly on whether or 
not they had first degree relatives with ovarian cancer (!2 = 4.78, p = .03) (see Tables 4 
and 5).  Women in the prophylactic mastectomy group were less likely to have first 
degree relatives with ovarian cancer. 
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Table 4 
Medical Characteristics of Participants Who Had Opted for Prophylactic Mastectomy 
versus Participants Who Had Not Opted for Prophylactic Mastectomy  
 
           Participants who Opted for      Participants who Did Not Opt for 
 Prophylactic Mastectomy  Prophylactic Mastectomy                        
  
 M (SD) M (SD)          t           p 
 
Body Mass Index  .17           .86 
  
  24.42 (4.63) 24.57  (5.0) 
 
 
 
Time Since Genetic Testing (in months) -.03 .77 
  
  33.36 (21.70) 32.16 (21.81)  
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Table 5 
Medical Characteristics of Participants Who Had Opted for Prophylactic Mastectomy 
versus Participants Who Had Not Opted for Prophylactic Mastectomy  
 
           Participants who Opted for      Participants who Did Not Opt for 
 Prophylactic Mastectomy  Prophylactic Mastectomy                        
  
 N (%) N (%)          X2                    p 
 
Tell Physician Test Results  .29         .59 
  
 Yes 35 (83%) 84 (88%) 
 No 7 (17%) 11 (12%) 
 
 
First Degree Relatives with Breast Cancer  .59 .44 
  
 Yes 33 (79%) 67 (71%) 
 No 9 (21%) 28 (29%) 
 
 
First Degree Relatives with Ovarian Cancer 4.78 .03* 
 
 Yes  4  (9%) 27 (28%) 
 No 36 (86%) 65 (69%) 
 Dont Know  2  (5%)  3  (3%) 
 
 
Menopausal Status 1.82 .18 
 
 Premenopausal  35 (83%) 88 (93%) 
 Menopausal  7 (17%)  7  (7%) 
  
 
45 
Relationship of Decision Making Variables to Choice of Risk-Reducing Option  
            The first hypothesis stated that the assessment of the pros and cons of 
prophylactic mastectomy would be associated with the type of risk-reducing option 
chosen.  As predicted, more positive scores on the Decisional Balance Scale for 
Prophylactic Mastectomy (pros-cons) (r = .31, p < .001) and higher scores on the pros 
items alone (r = .29, p < .001) were significantly related to having undergone 
prophylactic mastectomy surgery.  Also as predicted, higher scores on the cons items 
alone (r = -.25, p < .05) were significantly negative correlated with having undergone 
prophylactic mastectomy surgery (see Tables 6 and 7).   
46 
Table 6  
Correlational Analyses of Decision Making and Perceived Impact Variables With Group 
Status 
 
 
            Group Status 
 
Decisional Balance Scale for Prophylactic Mastectomy 
 Pros   .29** 
 Cons                                                                                               -  .25* 
 Total (Pros  Cons)   .31**    
Cancer Worry Scale 
 Past Month - .39***  
 When Genetically Tested  .28** 
 
Miller Behavioral Style Scale 
 Monitors     .01 
 Blunter  - .06 
 Total Score (Monitors  Blunters)  .04 
 
Center for Epidemiologic Studies-Depression Scale - .19* 
 
Decisional Conflict Scale - .38*** 
 
Decisional Regret Scale - .58*** 
 
*  p < .05 
** p< .001 
*** p < .0001 
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Table 7 
Comparisons between Participants Who Had Opted for Prophylactic Mastectomy versus 
Participants Who Had Not Opted for Prophylactic Mastectomy on Decision Making and 
Perceived Impact Variables  
 
              Did Not Opt for PM          Opted for PM               
  
 M (SD)             M     (SD)       t p 
 
Decisional Balance Scale for Prophylactic Mastectomy  
  
 Pros 12.99 2.72 14.74 2.51 -3.55  .0005**  
 Cons                           13.27 2.75 11.76 2.61      3.01   .0031*                                 
 Total (Pros  Cons)    -0.28 4.81  2.98 4.08 -3.83    .0002**  
 
 
Cancer Worry Scale 
 
 Past Month    7.61 2.78  5.19 2.45  4.87  <.0001*** 
 When Genetically Tested  10.37 3.57 12.50 2.78 -3.43    .0008**  
 
 
Miller Behavioral Style Scale 
 
 Monitors   10.06 3.35 10.14 3.38 -.13    .8982 
 Blunters    4.98 2.63  4.64 2.71  .68    .4957  
 Total Score (M-B)   5.08 4.35  5.50 4.69 -.50    .6153 
 
CES-D   12.02 10.15 8.10 7.51  2.52    .0133* 
 
Decisional Conflict Scale  35.49 20.51 18.56 16.42 4.72    <.0001*** 
 
Decisional Regret Scale   29.63 17.17 6.07 10.96 9.65  <.0001***  
 
 
*  p < .05 
** p< .001 
***  p < .0001 
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The second hypothesis stated that the treatment chosen would be related to 
recommendation of that treatment by a physician.  Specifically, if a physician had 
recommended prophylactic mastectomy, women would have been more likely to have 
chosen a prophylactic mastectomy.   Of the 137 women surveyed, 91 reported receiving 
at least one physicians opinion about the risk-reducing option she should pursue.  
Regarding the content of physician opinions, each group received an assortment of 
physician opinions (see Table 8 and 9) ranging from one type of risk-reducing option 
only (surveillance, prophylactic mastectomy, or chemoprevention) to a mixture of 
opinions for all three options.  Regarding recommendations for prophylactic mastectomy 
only, 71% of the prophylactic mastectomy group received doctor recommendations that 
included physician opinions only endorsing prophylactic mastectomy compared to 30% 
of the no prophylactic mastectomy group. Twenty-nine percent of the prophylactic 
mastectomy group and 70% of the no prophylactic group received opinions that included 
options other than prophylactic mastectomy alone.  These rates reflect a significant 
relationship between physician opinions that only included prophylactic mastectomy and 
risk-reducing option (prophylactic mastectomy versus no prophylactic mastectomy)  
(Χ2 = 11.85; p < .001) (see Table 10).  For the group as a whole, there was no relationship 
between whether or not a woman received a physician opinion about the risk-reduction 
option she should obtain and risk-reducing option (prophylactic mastectomy versus no 
prophylactic mastectomy) (Χ2 = .00, p = 1.000) (see Table 11).  However, the risk-
reducing groups did differ significantly on the number of doctor opinions received (t = -
2.59, p = .01) (see Table 12) with women who underwent prophylactic mastectomy 
receiving more doctor opinions.   
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Table 8 
Types of Doctor Recommendation for Women who Did Not Opt for Prophylactic 
Mastectomy 
 
 N  (%) 
 
Surveillance Only 23  (36%) 
Prophylactic Mastectomy Only 19  (30%) 
Chemoprevention Only  1  (2%) 
Mixed Recommendations 20  (32%) 
 
 
 
Table 9 
Types of Doctor Recommendation for Women who Did Opt for Prophylactic Mastectomy 
 
 N  (%) 
 
Surveillance Only 0  (0%) 
Prophylactic Mastectomy Only 20  (71%) 
Chemoprevention Only  0  (0%) 
Mixed Recommendations  8  (29%) 
 
 
Table 10 
Correlational Analyses of Doctor Recommendations with Group Status 
 
           Participants who Opted for      Participants who Did Not Opt for 
 Prophylactic Mastectomy  Prophylactic Mastectomy                        
  
 N (%) N (%)        X2                    p 
 
Doctor Treatment Recommendations              11.85              .0006 
  
 PM Only  20 (71%) 19 (30%) 
 Mixed  8 (29%) 44 (70%) 
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Table 11 
Correlational Analyses of Whether or Not MD Opinion was Obtained With Group Status 
 
           Participants who Opted for      Participants who Did Not Opt for 
 Prophylactic Mastectomy  Prophylactic Mastectomy                        
  
 N (%) N (%)                 X2         p 
 
 
Ask MD Opinion                        .00 1      .00 
  
 Yes 28 (67%) 63 (66%) 
 No 14 (33%) 32 (34%) 
 
 
Table 12 
Comparison Between Participants Who Had Opted for Prophylactic Mastectomy versus 
Participants Who Had Not Opted for Prophylactic Mastectomy on Number of MD 
Opinions 
 
 
Did Not Opt for PM          Opted for PM               
  
 M (SD) M (SD) t p 
      
Number of MD Opinions                     -2.59     .0111* 
  
 Prophylactic Mastectomy 2.82   (.98) 
 No Prophylactic Mastectomy 2.30 (.84) 
 
  
 
 
The third hypothesis stated that women with higher levels of cancer worry at time 
of genetic testing would be more likely to have chosen prophylactic surgery than women 
with lower levels of cancer worry.  As predicted, women who retrospectively reported 
higher cancer worry scores a month after receiving their BRCA1/2 positive results were 
more likely to have chosen prophylactic mastectomy (r = .28, p < .001) (see Tables 6 and 
7). 
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The fourth hypothesis stated that information-seeking style would be related to 
treatment choice with women with greater tendencies to use a monitoring information-
seeking style more likely to have chosen prophylactic surgery.  Contrary to predictions, 
there was no significant relationship found between information monitoring (r = .01, p = 
.8715) and risk-reduction option chosen. 
Exploratory analyses were undertaken to examine relationships among the 
variables found in the univariate analyses to be related to the risk-reducing option chosen.  
Specifically, the first analysis sought to identify which retrospective variables from the 
four decision making models provided the best fit for predicting risk-reducing choice in 
BRCA1/2 positive, healthy, unaffected women.  Because the dependent variable (risk-
reducing option) is dichotomous, a logistic regression analysis was performed using the 
following significant (p < .05) retrospective variables for the entire sample:  Decisional 
Balance Scale for Prophylactic Mastectomy and Cancer Worry Scale from time of 
genetic testing.  Using the forward selection method, the Decisional Balance Scale for 
Prophylactic Mastectomy was entered in first followed by the Cancer Worry score from 
the time of genetic testing.  The results (shown in Table 13) indicate that both measures 
were significant in the multivariate analyses.  Consistent with previous correlational 
analyses, having a higher Decisional Balance Scale for Prophylactic Mastectomy total 
score and higher retrospective Cancer Worry Scale score were associated with 
membership in the prophylactic mastectomy group.  Specifically, for every unit increase 
on the Decisional Balance Scale for Prophylactic Mastectomy total score the likelihood 
of being in the prophylactic mastectomy group increases by 21%.  Similarly, for every 
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unit increase on the retrospective Cancer Worry Scale the likelihood of being in the 
prophylactic mastectomy group increases by 30%.   
 
Table 13 
Multivariate Logistic Regression Predicting Risk Reducing Option Group Membership 
on Entire Sample 
 
________________________________________________________________________ 
 
 Variable   OR  95%   CI      p 
 
Decisional Balance Total Score  1.211  1.10   1.33 <.0001 
Cancer Worry Scale (at genetic testing) 1.298  1.13   1.49   .0002 
   
 
Note:  OR = odds ratio; CI = confidence interval 
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           A second logistic regression analysis was conducted on only the 91 participants 
who reported receiving advice on risk-reducing option from at least one physician.  Again 
in this case, the dichotomous dependent variable again was risk-reducing option.  The 
significant (p < .05), independent variables included the Decisional Balance Scale for 
Prophylactic Mastectomy, the Cancer Worry Scale from time of genetic testing, and 
treatment recommendation of prophylactic mastectomy exclusively.  Using the forward 
selection method, the treatment recommendation of prophylactic mastectomy only was 
entered in first followed by the Cancer Worry score from the time of genetic testing.  The 
Decisional Balance Scale for Prophylactic Mastectomy was not included in this model, as 
it did not meet the .05 significance level.  The results (shown in Table 14) indicate the 
two measures that were significant in multivariate analyses.  Having a physician 
recommendation for prophylactic mastectomy exclusively and higher Cancer Worry 
Scale scores at time of genetic testing were associated with membership in the 
prophylactic mastectomy group.  Specifically, having a doctor recommend prophylactic 
mastectomy exclusively increases the likelihood of being in the prophylactic mastectomy 
group by 625%.  Likewise, for every unit increase on the retrospective Cancer Worry 
Scale score the likelihood of being in the prophylactic mastectomy group increases by 
27%.  A possible explanation for the exclusion of the Decisional Balance Scale for 
Prophylactic Mastectomy in this model is that it is significantly correlated with treatment 
recommendations of prophylactic mastectomy variable are significantly correlated  
(r = -.38, p < .001). 
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Table 14 
Multivariate Logistic Regression Predicting Risk Reducing Option Group Membership 
the Subsample Who Reported Seeking Advice on Risk-Reducing Options from at Least 
One Physician  
 
________________________________________________________________________ 
 
 Variable   OR  95%   CI p 
 
Treatment Recommendation of PM only 6.255  2.20 17.76 .0006 
Cancer Worry Scale (at genetic testing) 1.266  1.06   1.51 .0081 
  
 
Note:  OR = odds ratio; CI = confidence interval 
 
Relationship of Perceived Impact Variables to Choice of Risk-Reducing Option 
A final set of analyses tested hypotheses that women who chose prophylactic 
mastectomy would experience less decisional conflict, less decisional regret, lower levels 
of depressive symptomatology, and lower levels of current cancer worry than women 
who did not choose prophylactic mastectomy.  As predicted, scores on the Decisional 
Conflict Scale, Decisional Regret Scale, CES-D and Cancer Worry Scale were all 
negatively correlated with risk-reducing option.  The direction of these relationships 
indicates that, as expected, having chosen prophylactic mastectomy was associated with 
less decisional conflict (r = -.38, p < .0001), decisional regret (r = -.58, p < .0001), 
depressive symptomatology (r = -.19, p < .05), and cancer worry (r = -.39, p < .0001) 
(see Tables 6 and 7).  
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Chapter Four 
 
Discussion 
 
            The primary goal of the present study was to explore the relationship between a 
set of theory-driven decision making variables and the actual treatment decisions made 
by a group of healthy, unaffected women who had tested positive for a BRCA1/2 gene 
mutation.  In addition, the perceived impact (conflict, regret, depressive symptomatology, 
and current cancer worry) of the treatment option selected was explored.  This discussion 
will review the findings, consider the limitations of the current study, and identify future 
research directions. 
Consistent with predictions, the choice of risk-reducing option (prophylactic 
mastectomy versus no prophylactic mastectomy) was associated with the following 
decision making variables:  assessment of advantages and disadvantages of risk reducing 
strategies, physician input, and past cancer worry.  Like in the normative decision making 
theory (Schwartz, Peshkin, et al., 2005; Armstrong et al., 2000; Lerman et al., 1996), 
women who rated the advantages of prophylactic mastectomy higher were more likely to 
have obtained a prophylactic mastectomy while women who had rated the disadvantages 
of prophylactic mastectomy as higher were less likely to obtain a prophylactic 
mastectomy.  As in the shared decision making theory (McNutt, 2004; Coulter, 2002), 
physician recommendations for prophylactic mastectomy only are significantly related to 
risk-reducing option (prophylactic mastectomy versus no prophylactic mastectomy) with 
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significantly more women from the prophylactic mastectomy group having received 
recommendations for prophylactic mastectomy only.  As suggested in affect based theory 
(Slovic, Finucane, Peter, & MacGregor, 2004; Ubel & Lowenstein, 1997; Schwartz, 
Peshkin, et al., 2005), women who retrospectively reported higher levels of cancer worry 
at time of genetic testing were more likely to have undergone prophylactic mastectomy.   
Finally, contrary to predictions based in previous research on information-seeking style 
(Miller, Roussi, Caputo, & Kruss, 1995), no relationship existed between monitoring 
information-seeking style and risk-reduction option. 
The predictive values of the significant, retrospective independent variables were 
looked at in two separate logistic regression models.  When the Decisional Balance Scale 
for Prophylactic Mastectomy and Cancer Worry Scale from time of genetic testing were 
included in the model they both contributed significantly to the chances of a women 
choosing prophylactic mastectomy in the entire sample.  In order to investigate the 
physician input variable, another logistic regression model was run only using the sample 
that had reported receiving an opinion on which risk-reducing option to undergo from at 
least one physician.  In this model, only the physician recommendation and Cancer 
Worry Scale from the time of genetic testing were found to contribute significantly to a 
women choosing prophylactic mastectomy. 
Finally, all the perceived impact variables (the Decisional Conflict Scale, 
Decisional Regret Scale, CES-D, and Cancer Worry Scale) were found to be negatively 
correlated with risk-reducing option.  As expected, women who opted for prophylactic 
mastectomy reported less decisional conflict, regret, depressive symptomatology, and 
cancer worry.  
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These findings expand the current decision making information literature with 
BRCA1/2 gene mutation carriers in three ways.  The first way involves the sample 
studied.  Past research has been conducted only on heterogeneous samples of women 
(e.g., affected and unaffected, BRCA1/2 gene mutation carriers, and various definitions of 
women at high risk) (Van Dijk et al., 2003; Stefanek et al., 1999; Armstrong et al., 2000). 
This study focuses only on women without a personal history of cancer who have tested 
positive for the BRCA1/2 gene mutation.   Therefore, all these women have the elevated 
chances of being diagnosed with breast and/or ovarian cancers in their lifetimes.   The 
second way this study extends the literature on decision making and BRCA1/2 is to 
investigate variables related to the decision of whether or not to opt for prophylactic 
mastectomy.  Although genetic testing decisions and prophylactic oophorectomy 
decisions have been studied previously, few studies have looked at decisions surrounding 
prophylactic mastectomy (Tercyak et al., 2007).  Finally, this study examined variables 
from four different decision making theories.  Previous research in this area has generally 
been more limited in scope.   
As noted in previous research on normative decision making, women who ranked 
the advantages of either genetic testing (Armstrong et al., 2000; Lerman et al., 1996) or 
prophylactic oophorectomy (Fry, Rush, Busby-Earle, & Cull, 2001) higher than the 
disadvantages were more likely to pursue these options.   Similar to this previous 
research, this study found that women who rated the advantages of prophylactic 
mastectomy higher than the disadvantages of prophylactic mastectomy were more likely 
to pursue prophylactic mastectomy.  This study is novel in that it investigates the 
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normative decision making theory in relation to whether or not BRCA1/2 gene mutations 
carriers without a history of cancer opt for prophylactic mastectomy.  
The shared decision making, or physician input, literature on genetic testing and 
treatment outcome suggests that physicians opinions were both desired (Armstrong et 
al., 2002) and a contributing factor in whether or not women pursued genetic testing 
(Schartz, Lerman, et al., 2005).  Likewise in this study, treatment recommendation for 
prophylactic mastectomy was significantly related to choice of prophylactic mastectomy 
in the women who sought out the opinion of one or more physicians. 
Previous research with the affect-based decision making theory suggests that 
higher cancer-related distress and worry lead women to pursue genetic testing (Lerman et 
al., 1997) and report higher intentions for prophylactic surgery (Van Dijk et al., 2003; 
Stefanek et al, 1999).  This research is similar to these studies.  Women who reported 
higher cancer worry at the time of genetic testing were more likely to obtain prophylactic 
mastectomies. 
Prior research on genetic counseling decisions and information-seeking style 
suggested that monitors are more likely to amplify the negative impact of testing (Lerman 
et al., 1994) and perceived risk (Sherman et al., 1995).  Extrapolating from these findings, 
we hypothesized that high monitoring BRCA1/2 genetic mutation carriers would amplify 
the negatives of their situation and amplify their risks thereby resulting in more 
prophylactic mastectomy decisions.  Unlike the previous research on information-seeking 
style, greater use of a monitoring coping style was not related to risk-reducing option 
choice.  This discrepancy may have something to do with the women sampled.  Women 
who frequent the FORCE website are likely to be actively seeking out information on 
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their BRCA1/2 status (i.e., monitoring).  Therefore, women with blunting coping styles 
may have been less likely to have accessed the study through this information-based 
website.  
Previous research has examined the relationship of BRCA1/2 gene mutation status 
to quality of life and psychological distress.  Tercyak et al. (2007) report on the quality of 
life and psychological distress of a sample of breast cancer patients with either positive 
results (15%) or uninformative results (85%).  Whether or not women chose to undergo 
contralateral prophylactic mastectomy (versus unilateral mastectomy or lumpectomy) did 
not predict short-term quality of life or cancer-specific distress.  In a study most similar to 
the present study, Madalinkska et al. (2005) compare high-risk women who opt for 
periodic gynecologic screening versus prophylactic bilateral salpingo-oophorectomy.  
While no significant differences were found in generic quality of life, the group opting 
for prophylactic oophorectomy did report significantly less worries specific to breast and 
ovarian cancers and lower cancer risk perceptions.  These results are similar to findings 
from the present study which suggest that women who chose prophylactic mastectomy 
are actually doing better psychologically in terms of experiencing lower levels of current 
cancer worry and depressive symptomatology than women who did not opt for 
prophylactic mastectomy.  Besides a measure of general quality of life (e.g., depressive 
symptomatology) and cancer specific worry, the present study includes variables of 
decisional conflict and decisional regret.  This is similar to finding for decisional regret 
(Borgen et al., 1998) in which the majority of women (n = 349) who signed up for the 
National Prophylactic Mastectomy Registry between 1945 and 1996 did not express 
regret over their decision to undergo prophylactic mastectomy.  Likewise, in a small 
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study (N = 14) on decisional satisfaction (Stefanek, Helzlsouer, Wilcox, & Houn, 1995) 
with women at high risk, satisfaction with prophylactic mastectomy was high for all 
participants.  Therefore this study expands the psychological variables studied and 
focuses exclusively on a positive BRCA1/2 sample.  
Limitations 
            This study had several limitations.  Without a valid and reliable measure of the 
perceived advantages and disadvantages of undergoing prophylactic mastectomy 
available in the literature, the Decisional Balance Scale for Prophylactic Mastectomy was 
specifically designed for this study.  This measure was developed by taking items on the 
assessment of advantages and disadvantages of prophylactic mastectomy by women at 
increased risk for breast cancer from the literature (Claes, et al., 2005).  Coefficient 
alphas calculated in the study were weak (.48 for the advantages scale and .44 for the 
disadvantages scale), suggesting the findings involving this measure be cautiously 
considered.     
            The physician input variables possessed a number of weaknesses.    These 
variables included whether or not a physician gave his/her opinion regarding risk-
reducing strategy, how many different physician opinions were obtained, and the specific 
nature of the recommendations.   While 42 women in this sample underwent prophylactic 
mastectomies, only 28 women reported receiving a physicians opinion regarding risk-
reducing strategies.  However, all 42 women had to have worked with surgeons willing to 
perform their prophylactic mastectomies.  Assuming they did not undergo prophylactic 
mastectomy against medical advice, all 42 women of these women had in a sense 
received opinions from at least one doctor regarding risk-reducing strategies.  
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Because of the cost of gene mutation testing (Peterson, Milliron, Lewis, Goold, & 
Merajver, 2002), the profile of FORCE members, and the need to have Internet access, it 
was no surprise that the sample for the current study was made up primarily of 
Caucasian, well-educated, higher income women.  This feature limits the generalizability 
of these findings to populations more diverse with regard to race/ethnicity, education, and 
socioeconomic status.   
              In order to attain a sample of positive, unaffected women of this size, an 
anonymous web-based survey was necessary.  This method of data collection has 
drawbacks in regards to limited access and limited tracking ability.  As stated above, only 
women who had access to the Internet were able to participate.  In addition, there was no 
way to track the response rate to determine if a systematic bias existed connected with 
whether or not a woman agreed to participate.  Finally, based on same birthdates and 
similar demographic data, ten women were found to have completed the survey more 
than once.    
Limitations of this study also exist because of the retrospective, self-report, cross-
sectional nature of this study.   Three of the measures (Decisional Balance Scale for 
Prophylactic Mastectomy, Cancer Worry Scale at time of genetic testing, and the 
Decisional Conflict Scale) asked respondents to provide retrospective information.  
Although care was taken in the instructions to provide context by cueing participants to 
both the season of the year and major events that coincided with their genetic testing, the 
accuracy of the recalled responses is impossible to verify.  In addition, all data were   
collected via self-report without any means to verify that all eligibility criteria had been 
met or the accuracy of the medical information provided, including recommendations for 
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risk reduction.  Ideally, corroborating medical data would also have been collected from 
medical care providers.  Finally, the cross-sectional design limits the ability to make 
conclusions about the causal relationships between the decision making variables and the 
risk-reducing options chosen.   
Future Directions 
The research designs of future studies could be improved in several ways.  More 
information about decision making variables for risk-reducing options could be obtained 
by designing prospective studies including pre-genetic testing baseline assessments.   
Therefore, differences between individuals prior to testing could be identified.  In 
addition, a longitudinal research design would allow for a better understanding of the 
variables that go into risk-reducing decisions, as well as the impact of these risk-reducing 
decisions over time.  Because women with the BRCA1/2 gene mutation are at increased 
risk for both breast and ovarian cancers (Antoniou et al., 2003), future research should 
broaden the scope of risk-reducing options studied in these healthy, unaffected BRCA1/2 
gene mutation carriers.  In contrast to the present study that focused only on the decision 
to undergo prophylactic mastectomy, future research should include decision making 
variables for prophylactic oophorectomy, as well as chemoprevention as the use of this 
option increases.    
Data from this study suggest women who do not opt to undergo prophylactic 
mastectomy are experiencing higher levels of cancer worry, decisional conflict, 
decisional regret, and depressive symptomatology when compared to the women who do 
undergo prophylactic mastectomies.  In order for healthy, unaffected, gene mutation 
carriers to make informed risk-reducing decisions, information on the psychological 
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distress of not opting for prophylactic mastectomy needs to be available.  No studies of 
this kind could be found in the current literature.  Future research should focus on the 
degree of distress experienced by this sample of healthy, unaffected, gene mutation 
carriers who do not opt for prophylactic mastectomy, along with the best ways to provide 
psychological services if and when necessary. 
The current study includes only women who received a positive genetic test 
results.  However, a woman may receive ambiguous (i.e., indeterminate) BRCA1/2 test 
results.  In these cases, the test may show a BRCA1/2 mutation that has yet to be 
correlated with breast or ovarian cancers.  Because women tested for the BRCA1/2 gene 
mutation may receive ambiguous results, ultimately more future research should include 
large enough samples of women who have received indeterminate results in order to 
establish if and how their decision making differs from women who receive positive test 
results.  Finally, all future studies should strive to recruit larger, more demographically 
diverse samples in order to generalize study findings.   
Summary 
This study addresses a salient issue that BRCA1/2 gene mutation carriers face.  
Prior to this study, little was known about the decision making factors underlying the 
choice of prophylactic mastectomy for women with a BRCA1/2 mutation.  One hundred 
thirty-seven unaffected, positive gene mutation carriers were assessed via an on-line 
survey on the following theory-based decision making variables:  advantages and 
disadvantages of prophylactic mastectomy (normative decision theory), physician 
recommendation (shared decision making theory), cancer worry (affect theory), and 
information-seeking coping style.  The results suggest higher assessments of advantages 
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over disadvantages of prophylactic mastectomy, likelihood of doctor recommendation for 
prophylactic mastectomy exclusively, and higher cancer worry at time of testing are 
associated with choosing the risk-reducing option of prophylactic mastectomy.  
Additional findings suggested that women who chose prophylactic mastectomy fared 
better psychologically than those who did not in terms of experiencing less decisional 
conflict and regret as well as lower levels of cancer worry and depressive 
symptomatology. Continued research addressing decision making variables and the 
impact of risk-reducing decisions may lead to improved understanding and interventions 
on how best to approach these difficult decisions. 
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Appendix A:  Pilot Participant Telephone Script 
Hello, my name is Heidi King and I am calling from the Moffitt Cancer Center.  Sue 
Friedman provided me with your name as someone who might be interested in 
completing a survey we are piloting for one of our new studies.   
Have you spoken with Sue Friedman? 
Is now a good time to tell you a bit more about the study? 
We are interested in finding out how women who have tested positive for the BRCA1/2 
gene mutation go about making decisions to reduce their risk of breast cancer.  The 
survey is posted on-line.  Before we open the study up to the general population, we 
would like to verify the length of time it takes to complete the study, as well make sure 
all the questions are clearly stated.   
Does this sound like something you might be interested in? 
 
I have a few questions to ask you to ensure this pilot study is a good fit for you. 
 
1. Have you tested positive for the BRCA1/2 gene mutation? _________Must be 
+. 
 
2. When was that?  _________Must be at one year or more ago. 
 
3. Have you ever been diagnosed with any type of cancer?  _________  
 Only exception is basal cell cancer. 
 
4. Have you had a prophylactic oophorectomy (the removal of healthy ovaries in 
order to reduce your risk of cancer)?  _________ Must be no. 
 
5. May I ask your age?  __________Must be 18 or older. 
 
6. Are you comfortable reading English?________ 
 
7. Do you have access to the Internet?________ 
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Appendix B:  Informed Consent for Pilot Study 
 
Informed Consent Form 
Social and Behavioral Sciences  
University of South Florida 
Researchers at the University of South Florida (USF) study many topics.  We want to 
learn more about how women who are BRCA1/2 gene mutation carriers go about making 
decisions about reducing their risk of breast cancer.  To do this, we need the help of 
people who agree to take part in research studies.   
 
Title of research study:   Pilot Study for Risk Reduction Decision Making in Women 
with BRCA1/2 Gene Mutations 
 
Person in charge of study:   Paul Jacobsen, PhD 
 
Study staff who can act on behalf of the person in charge:  Heidi M. King, MA 
 
    Where the study will be done:  H. Lee Moffitt Cancer Center 
General Information about the Research Study 
The purpose of this pilot study is to verify the length of time it takes to complete the 
survey on how women who are BRCA1/2 gene mutation carriers go about making 
decisions about whether or not to undergo prophylactic mastectomies (surgical removal 
of healthy breast tissue in order to reduce the risk of breast cancer) to reduce their risk of 
breast cancer.  In addition, we need to ensure that the wording of all questions are clearly 
stated and fully understood by individuals completing the survey. 
Plan of Study 
If you agree to participate, you will be asked to complete a one-time, on-line 
questionnaire that does not ask for identifying information beyond your birthday and 
general demographic information.  It should take you approximately 25 minutes to 
complete this on-line survey.  Then a researcher will call you on the phone to go over the 
items to ensure that they were clearly stated. 
 
Payment for Participation 
There will be no financial compensation for participating in this study. 
 
Benefits of Being a Part of this Research Study 
You will not benefit directly by participating.  However, the information you provide will 
help ensure that the survey is clearly worded prior to being disseminated. 
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Appendix B:  Informed Consent for Pilot Study (Continued) 
Risks of Being a Part of this Research Study 
We do not foresee any risk to you in participating in this study. 
 
Confidentiality of Your Records 
The information provided will be kept confidential to the extent feasible using the 
Internet.  All electronic study data will be password protected with access restricted to 
approved personnel.  However, certain people may need to see your study records.  By 
law, anyone who looks at your records must keep them confidential.  The only people 
who will be allowed to see these records are: 
• Study staff. 
• People who make sure that we are doing the study in the right way.  They also 
make sure that we protect your rights and safety: 
o The USF Institutional Review Board (IRB) 
o The United States Department of Health and Human Services (DHHS) 
 
" Volunteering to be Part of this Research Study 
Your decision to participate in this research study is completely voluntary.  You are free 
to participate in this research study or to withdraw at any time.  If you to choose not to 
participate, or if you withdraw, there will be no penalty or loss. 
 
" Questions and Contacts 
o If you have any questions about this research study, contact Heidi King, 
MA at  
1-800-456-3434 X4606 or Dr. Paul Jacobsen at 813-632-1810. 
 
o If you have questions about your rights as a person who is taking part in a 
research study, you may contact a member of the Division of Research 
Compliance at the University of South Florida at 813-974-5638. 
 
Consent to Take Part in this Research Study 
It is up to you.  You can decide if you want to take part in this study. 
I freely give my consent to take part in this study.  I understand that this is research.  
I have received a copy of this consent form. 
 
________________________ ________________________ ___________ 
Signature  Printed Name  Date 
of Person taking part in study of Person taking part in study 
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Appendix B:  Informed Consent for Pilot Study (Continued) 
Statement of Person Obtaining Informed Consent 
I have carefully explained to the person taking part in the study what he or she can 
expect.  
The person who is giving consent to take part in this study 
• Understands the language that is used. 
• Reads well enough to understand this form.  Or is able to hear and understand 
when the form is read to him or her. 
• Does not have any problems that could make it hard to understand what it means 
to take part in this study.  
• Is not taking drugs that make it hard to understand what is being explained.   
 
 
To the best of my knowledge, when this person signs this form, he or she understands: 
• What the study is about. 
• What needs to be done. 
• What the potential benefits might be.  
• What the known risks might be. 
• That taking part in the study is voluntary. 
 
________________________ ________________________ ___________ 
Signature of Investigator Printed Name of Investigator Date 
or authorized research 
investigator designated by 
the Principal Investigator 
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Appendix C:  First Website Screen--Eligibility Criteria 
 
Study of Risk Reduction Decision Making in Women with BRCA1/2 Gene Mutations 
The purpose of this study is to learn more about how women who are BRCA1/2 gene 
mutation carriers go about making decisions about ways to reduce their risk of breast 
cancer. You will be asked to complete an on-line survey that takes approximately 25 
minutes. Your participation in this study is anonymous to the extent possible using the 
Internet.  
To participate in this study, you must meet all of the following conditions: 
• You are a woman. 
• You underwent genetic testing for the BRCA1/2 gene mutation one year or more 
ago. 
• You have tested positive for the BRCA1/2 gene mutation. 
• You have never been diagnosed with breast cancer. 
• You have never been diagnosed with any other type of cancer (with the exception 
of basal cell skin cancer). 
• You have not undergone a prophylactic oophorectomy (surgical removal of 
healthy ovaries in order to reduce the risk of breast and/or ovarian cancers). 
• You are at least 18 years old. 
• You are able to read and understand English. 
CLICK HERE IF YOU 
MEET ALL  
OF THESE CONDITIONS 
 
CLICK HERE IF YOU 
DO NOT MEET 
ALL OF THESE 
CONDITIONS 
 
 
 
Ineligible Message: 
Thank you for your interest.  However, at this time, you do not meet eligibility criteria for 
this study.  Have a great day! 
 
Eligible Message: 
You are eligible to participate in the study!  Please read through the full description of the 
study provided below to become informed about any risks and benefits as a result of your 
participation.  Please click on Agree or Do Not Agree at the bottom of the page once 
you have read through the entire informed consent. 
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Appendix D:  Informed Consent for Study Participants 
 
Informed Consent Form 
Social and Behavioral Sciences  
University of South Florida 
Researchers at the University of South Florida (USF) study many topics.  We want to 
learn more about how women who are BRCA1/2 gene mutation carriers go about making 
decisions about reducing their risk of breast cancer.  To do this, we need the help of 
people who agree to take part in research studies.  You are being asked to participate 
because you have met the following eligibility criteria: 
1) You are a woman. 
2) You have tested positive for the BRCA1/2 gene mutation one year or more 
ago. 
3) You have never been diagnosed with breast cancer, or any other type of 
cancer (with the exception of basal skin cancer).  
4) You have not undergone a prophylactic oophorectomy (surgical removal of 
healthy ovaries in order to reduce the risk of breast and/or ovarian cancers). 
5) You are at least 18 years old. 
6) You are able to read and understand English. 
 
Title of research study:   Risk Reduction Decision Making in Women with 
BRCA1/2 Gene Mutations 
 
Person in charge of study:   Paul Jacobsen, PhD 
 
Study staff who can act on behalf of the person in charge:  Heidi M. King, MA 
 
    Where the study will be done:  H. Lee Moffitt Cancer Center 
General Information about the Research Study 
The purpose of this research study is to learn more about how women who are BRCA1/2 
gene mutation carriers go about making decisions about whether or not to undergo 
prophylactic mastectomies (surgical removal of healthy breast tissue in order to reduce 
the risk of breast cancer) to reduce their risk of breast cancer. 
Plan of Study 
If you agree to participate, you will be asked to complete a one-time, on-line 
questionnaire that does not ask for identifying information beyond your birthday and 
general demographic information.  It should take you approximately 25 minutes to 
complete this on-line survey. 
Payment for Participation 
There will be no financial compensation for participating in this study. 
 
81 
Appendix D:  Informed Consent for Study Participants (Continued) 
Benefits of Being a Part of this Research Study 
You will not benefit directly by participating.  However, the information you provide will 
help researchers better understand decision making in BRCA1/2 mutation carriers. 
Risks of Being a Part of this Research Study 
We do not foresee any risk to you in participating in this study. 
Confidentiality of Your Records 
You will be anonymously participating in this study to the extent feasible using the 
Internet.  All electronic study data will be password protected with access restricted to 
approved personnel. 
However, certain people may need to see your study records.  By law, anyone who looks 
at your records must keep them confidential.  The only people who will be allowed to see 
these records are: 
• Study staff. 
• People who make sure that we are doing the study in the right way.  They also 
make sure that we protect your rights and safety: 
o The USF Institutional Review Board (IRB) 
o The United States Department of Health and Human Services (DHHS) 
We may publish what we find out from this study.  However, the data obtained from you 
will be combined with data from other people in the publication.  We will not be 
collecting or disclosing any identifying information about you. 
 
" Volunteering to be Part of this Research Study 
Your decision to participate in this research study is completely voluntary.  You are free 
to participate in this research study or to withdraw at any time.  If you to choose not to 
participate, or if you withdraw, there will be no penalty or loss. 
 
" Questions and Contacts 
o If you have any questions about this research study, contact Heidi King, 
MA at 1-800-456-3434 X4606 or Dr. Paul Jacobsen at 813-632-1810. 
 
o If you have questions about your rights as a person who is taking part in a 
research study, you may contact a member of the Division of Research 
Compliance at the University of South Florida at 813-974-5638. 
 
By clicking the agree button below, you indicate that you have read and understood the 
information above including any possible risks and benefits of participation.  You also 
indicate that you agree to participate in this study. 
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Appendix E:  General Background Information 
1.  Today's date: ρρ/ρρ/ρρρρ (month/day/year)  
 
2. Birth date: ρρ /ρρ/ ρρρρ (month/day/year) 
 
3.  Height: ρ (ft) ρρ (in)   
 
4. Weight: ρ ρ ρ (pounds) 
 
 
5.  Are you: 
 
 ρ   Hispanic or Latino 
 ρ   Not Hispanic or Latino 
 
6. Race: 
 
ρ   American Indian or Alaska Native      ρ Native Hawaiian/other Pacific Islander    
 ρ   Asian           ρ White 
 ρ   Black or African American     ρ  More than one race 
  
7.  Are you of Ashkenazi Jewish heritage?  
 
 ρ   Yes 
 ρ   No 
 
8. Marital status: 
 
 ρ    Never married      ρ    Divorced 
ρ    Currently married  ρ    Widowed 
ρ    Separated 
 
 
9.   Number of children under 18:   ρ ρ 
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Appendix E:  General Background Information (Continued) 
 
`10. Current living arrangement : 
 
 ρ    Live alone ρ    Live with roommate who is not partner 
 ρ    Live with spouse/partner     ρ    Live with parents                                                  
 ρ    Live with children (no spouse/partner)  ρ    Other    (specify)__________ 
      
 
11. How long in current living arrangement: 
 
 ρ     Less than 1 month    ρ    Two to 5 years 
ρ     One to 6 months       ρ    More than 5 years 
ρ     Seven months to 2 years 
 
 
12. Highest level of school completed: 
 
 ρ    Less than 7th grade     ρ   Partial college/specialized training 
ρ    Partial high school (10th or 11th grade)       ρ   College or university graduate 
ρ    High School graduate   ρ   Graduate professional training   
                (graduate degree)  
 
13. Approximate annual gross income for your household:   
 
 ρ       Less than $ 10,000  ρ    $40,000 - $59,999 
        ρ       $10,000 - $19,999  ρ    $60,000 - $100,000 
         ρ       $20,000 - $ 39,999  ρ    Greater than $100,000 
     ρ    Prefer not to answer 
                                                             
Genetic Testing Information 
14.  Who referred you for genetic testing?  
 
   No one, I referred myself  
   A family member  
   An oncologist 
   A surgeon  
   A primary care provider (family physician) 
   A gynecologist 
   A nurse 
   Other  (describe _________________________________) 
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Appendix E:  General Background Information (Continued) 
 
15. When did you receive your genetic test results?  
   
 Month      Year  
 
16.  Did you share these results with your primary care doctor?  
 No 
 Yes 
   
Family History for Breast and/or Ovarian Cancer 
17.  Have any of your biological first degree relatives (i.e., your mother, your sister(s), or 
your daughter(s)) ever had breast cancer?  
   No  (if checked, skip to item 18) 
    Dont know (if checked, skip to item 18) 
   Yes  
        
17a.  Who?     
   One First Degree Relative 
  Two First Degree Relatives 
  Three First Degree Relatives  
  More than Three First Degree Relatives 
      ! 
17b.  Were any of them first told they had breast cancer at before age 50?  
   No  
   Yes   
         ! 
17c.  How close is/was your relationship with this relative (if more than one relative had 
breast cancer, please rate for the relative you feel/felt closest to)?  
    Not at all close 
    Somewhat close 
    Very close 
 Extremely close 
 
        
" 
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Appendix E:  General Background Information (Continued) 
 
18.  Have any of your biological first degree relatives (i.e., your mother, your sister(s), or 
your daughter(s)) ever had ovarian cancer?  
   No  (if checked, skip to item 19) 
    Dont know (if checked, skip to item 19) 
   Yes  
        
18a.  Who?     
   One First Degree Relative 
  Two First Degree Relatives 
  Three First Degree Relatives  
  More than Three First Degree Relatives 
      ! 
18b.  Were any of them first told they had breast cancer before age 50?  
   No  
   Yes   
 
         ! 
18c.   How close is/was your relationship with this relative (if more than one relative had 
ovarian cancer, please rate for the relative you feel/felt closest to)?  
    Not at all close 
    Somewhat close 
    Very close 
 Extremely close 
 
                   
  
 
 
 
 
 
 
 
 
        
" 
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Appendix E:  General Background Information (Continued) 
 
Risk-Reducing Options Chosen 
 
19.  Have you undergone a prophylactic mastectomy (surgical removal of healthy breast 
tissue in order to reduce the risk of breast cancer)? 
  
  No (if checked, go to Item 20). 
  Yes (if checked, go to Item 19a)   
 
19a. When did you undergo prophylactic mastectomy?  
   
 Month      Year  
 
Perceived Risk 
19b. Prior to undergoing  prophylactic mastectomy, how likely did you think you were to 
have breast cancer during your lifetime?  
 
    Extremely unlikely 
    Very unlikely 
    Somewhat unlikely 
       Somewhat likely 
       Very likely 
       Extremely likely  
 
19c. Prior to undergoing  prophylactic mastectomy, what did you think your chances were of 
having breast cancer in your lifetime compared to other women your age?  
   
   Much higher  
   Somewhat higher  
   About the same  
   Somewhat lower  
   Much lower  
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Appendix E:  General Background Information (Continued) 
 
20. At this time, how likely do you think you are to have breast cancer during your lifetime?  
 
    Extremely unlikely 
    Very unlikely 
    Somewhat unlikely 
       Somewhat likely 
       Very likely 
       Extremely likely  
 
 
21.  At this time, what do you think your chances are of having breast cancer in your lifetime 
compared to other women your age?  
   
   Much higher  
   Somewhat higher  
   About the same  
   Somewhat lower  
   Much lower PM Group now jumps to Item 34 
Intentions 
 
22.  In the next 6 months, how likely are you to undergo prophylactic mastectomy?  
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
Extremely 
Unlikely 
 
Unlikely 
 
 
Not Sure 
 
Likely 
 
 
Extremely  
Likely 
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Surveillance Behaviors 
 
23.  A breast self-examination involves examining your own breasts to help identify any 
lumps or changes in your normal breast tissue.  Have you performed a breast self-
examination for the detection of breast cancer in the past month? (check one box)  
   
    No 
    Yes 
 
24.  How often have you performed breast self-examination for the detection of breast 
cancer in the past year? 
   
    Not at all 
    Less than once a month 
    About once a month 
    More than once a month 
 
25.  How often do you plan on doing a breast self-examination in the next year?  
 
  Not at all 
  Less than once a month  
  About once a month 
  More than once a month 
 
26.  How confident do you feel in your ability to perform breast self-examination? (check 
one box) 
 
    Not at all confident 
    A little confident 
    Fairly confident 
    Very confident 
 Extremely confident 
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Appendix E:  General Background Information (Continued) 
 
27. Please indicate the extent to which you agree or disagree with each of the following 
statements about a breast self-examination as they apply to women who are BRCA1 or 
BRCA2 positive: 
 
 Strongly 
Disagree 
Disagree Neither 
Agree/  
Disagree 
Agree Strongly 
Agree 
a. A woman would be less anxious  
if she did a monthly breast self-  
examination 
     
b. If a woman does a breast           self-
examination, she may find      lumps 
before her regular check-up.         
     
c. A woman would gain a lot by doing 
breast self-examinations...      
d. Breast self-examinations can  
    prevent future 
problems... 
     
e. Breast self-examinations will 
improve a womans 
health 
     
  
28.  Have you had a breast exam conducted by a medical professional for the detection of 
breast cancer in the past year? 
 
   Yes 
   No -  If no, why not?  
     No reason 
     My doctor(s) did not recommend it 
     I didnt think I needed it 
  I put it off or didnt get around to it 
  I couldnt afford it  
  I thought it would be too painful, unpleasant, or embarrassing 
  I never heard of it 
  I didnt have any problems or symptoms 
  I thought I was too young or too old to have it done 
Other (please explain) 
_______________________________________________) 
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29. How many breast exams conducted by a medical professional for the detection of 
breast cancer have you had in the past 3 years?  
        (check one box) 
          
        0   1             2             3             4 or more 
 
 
30. Have you had a mammogram for the detection of breast cancer in the past year? 
 
   Yes 
   No -  If not, why not? 
     No reason 
     My doctor(s) did not recommend it 
     I didnt think I needed it 
  I put it off or didnt get around to it 
  I couldnt afford it  
  I thought it would be too painful, unpleasant, or embarrassing 
  I never heard of it 
  I didnt have any problems or symptoms 
  I thought I was too young or too old to have it done 
   Other (please explain 
_______________________________________________) 
 
31. How many mammograms for the detection of breast cancer have you had in the past 3 
years?  
          
        0   1             2             3             4 or more 
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32.  Have you had magnetic resonance imaging (MRI) for the detection of breast cancer 
in the past year? 
 
   Yes 
   No -  If no, why not?  
     No reason 
     My doctor(s) did not recommend it 
     I didnt think I needed it 
  I put it off or didnt get around to it 
  I couldnt afford it  
  I thought it would be too painful, unpleasant, or embarrassing 
           I never heard of it 
  I didnt have any problems or symptoms 
  I thought I was too young or too old to have it done 
  Other (please explain) 
_______________________________________________ 
 
33. How many MRIs for the detection of breast cancer have you had in the past 3 years?  
         
 
          
            0  1             2             3             4 or more 
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34. Have you ever had any cosmetic surgery on your breasts?  
 No  (If checked, go to Item 35.) 
   Yes (If checked, go to 34a.) 
 
34a. What surgery?  
ρ Reconstruction following prophylactic mastectomy 
 ρ  Breast augmentation 
 ρ  Breast reduction 
 ρ  Other 
 
35.  In the future, how likely are you to undergo a prophylactic oophorectomy (the 
surgical removal of healthy ovaries to reduce your risk of breast cancer)?   
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
Extremely 
Unlikely 
 
Unlikely 
 
 
Not Sure 
 
Likely 
 
 
Extremely  
Likely 
 
 
Menopausal Status Questionnaire 
 
 
36. Have you ever had a hysterectomy (i.e., removal of the womb)? 
 ρ No 
 ρ Yes 
 ρ Don't know 
 
37. Have you ever had one or both of your ovaries removed? 
 
 ρ No, neither of my ovaries have been removed 
 ρ Yes, one ovary removed 
 ρ Yes, both ovaries removed 
 ρ Do not know 
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Appendix E:  General Background Information (Continued) 
 
38. Have you received any hormone replacement therapy within the past week (i.e., 
estrogen)? 
 
 ρNo 
 ρYes 
 ρDon't know 
 
39. Have you ever received hormone replacement therapy (i.e., estrogen)? 
  
                                               ρ No 
 ρ Yes 
 ρ Don't know 
 
40. Have you had a menstrual period within the past 3 months? 
 
ρNo 
 ρYes 
 ρDon't know 
 
41. Have you had a menstrual period within the past 12 months? 
 ρNo 
ρYes 
 ρDon't know 
 
42. Compared with 12 months ago, are your menstrual periods in the past 3 months, less 
regular, about the same, or more regular? 
ρI have not had a menstrual period within the past 3 months  
 ρLess regular 
 ρAbout the same 
 ρMore regular 
              ρDon't know 
 
43. Are you currently taking Tamoxifen / Nolvadex? 
 
ρNo 
ρYes 
   
44. Are you currently taking Raloxifine / Evista? 
 
ρNo 
ρYes 
 
45. Are you currently taking Anastrazole / Arimidex? 
 
ρNo 
ρYes 
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Appendix E:  General Background Information (Continued) 
 
46. Are you currently taking Letrezole / Femara? 
 
ρNo 
ρYes 
 
47. Are you currently taking Toremifine / Fareston? 
 
ρNo 
ρYes 
 
48. Are you currently taking Exemstrane / Aromasin? 
 
ρNo 
ρYes 
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Appendix F:  Decisional Balance Scale for Prophylactic Mastectomy 
 
Below is a list of issues that a woman who is BRCA1 or BRCA2 positive might have 
considered when deciding whether or not to pursue prophylactic mastectomy.  Think 
back to the time after you received your BRCA1 or BRCA2 results and were deciding 
about whether to undergo prophylactic mastectomy.  Think about what season of the year 
it was.  Think about the month it was.  Think about the major holidays that occurred 
around this time.  Most importantly, try to remember how were feeling, as well as what 
you were thinking around the time you considered whether or not to undergo a 
prophylactic mastectomy.  Please read each item below and indicate the degree to which 
you believe you agreed or disagreed with each item when considering prophylactic 
mastectomy. 
 
At the time I was deciding about  
prophylactic mastectomy. 
 
Strongly 
Agree 
 
 
Agree 
Neither 
Agree 
Or 
Disagree 
 
 
Disagree 
 
Strongly 
Disagree 
49A. I believed prophylactic mastectomy 
         would substantially reduce my risk 
         of breast cancer. 
 
 
 
 
 
 
 
 
 
 
49B.  I was concerned about how 
prophylactic 
   mastectomy would affect my 
physical 
   appearance. 
 
 
 
 
 
 
 
 
 
 
49C. I thought I would worry much less  
   about getting breast cancer if I  
   had prophylactic mastectomy. 
 
 
 
 
 
 
 
 
 
 
49D. I was not seriously concerned about 
the 
         surgical risks involved with  
         prophylactic mastectomy. 
 
 
 
 
 
 
 
 
 
 
49E. I believed having prophylactic  
  mastectomy would not affect  
  how I viewed my body. 
 
 
 
 
 
 
 
 
 
 
49F.  I believed the recovery period  
  following prophylactic  
  mastectomy would be too 
  physically draining for me. 
 
 
 
 
 
 
 
 
 
 
49G. I believed having a prophylactic  
  mastectomy would negatively  
  affect my sex life. 
 
 
 
 
 
 
 
 
 
 
49H. I believed, following prophylactic  
   mastectomy, I would still be 
concerned  
  with my risk for breast cancer. 
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Appendix G:  Physician Input 
 
50.  Did a doctor give his/her opinion to you about the risk-reducing strategy (for example, 
prophylactic mastectomy or mammography) you should choose? 
 
ρ No (Go to .) 
 ρ Yes (Go to # 50a) 
 
50A.  Did more than one doctor give his/her opinion about the risk-reducing strategy you should     
choose? 
 
ρ No (Go to #50C) 
 ρ Yes (Go to #50B) 
 
50B.  How many doctors made recommendations? 
 
ρ ρ ρ  
 2  3  4  
 
 What did each doctor recommend? 
50C.  Doctor #1 most strongly recommended: 
 
ρ Surveillance (e.g., breast self-exam, clinical breast exam, mammography) 
 ρ Prophylactic mastectomy 
ρ Chemoprevention (i.e., use of medications to prevent breast cancer) 
 
 
50D.  Doctor #2 most strongly recommended: 
 
ρ Surveillance (e.g., breast self-exam, clinical breast exam, mammography) 
 ρ Prophylactic mastectomy 
ρ Chemoprevention (i.e., use of medications to prevent breast cancer) 
 
50E.  Doctor #3 most strongly recommended: 
 
ρ Surveillance (e.g., breast self-exam, clinical breast exam, mammography) 
 ρ Prophylactic mastectomy 
ρ Chemoprevention (i.e., use of medications to prevent breast cancer) 
 
50F.  Doctor #4 most strongly recommended: 
 
ρ Surveillance (e.g., breast self-exam, clinical breast exam, mammography) 
 ρ Prophylactic mastectomy 
ρ Chemoprevention (i.e., use of medications to prevent breast cancer) 
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Appendix H:  Cancer Worry Scale 
During the past month . . . 
51. How often have you been concerned about getting breast cancer? 
 
     
 Not at all Sometimes Often A lot 
 or Rarely 
 
52. How often have you thought about your own chances of having breast cancer? 
 
     
 Not at all Sometimes Often A lot 
 or Rarely 
 
53. How often have thoughts about breast cancer affected your mood? 
 
     
 Not at all Sometimes Often A lot 
 or Rarely 
 
54. How often have thoughts about breast cancer affected your ability to perform your 
daily activities? 
 
     
 Not at all Sometimes Often A lot 
 or Rarely 
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Appendix I:  Retrospective Cancer Worry Scale 
 
Think back to the time after you received your BRCA1 or BRCA2 results.  Think about 
what season of the year it was.  Think about the month it was.  Think about the major 
holidays that occurred around this time.  Most importantly, try to remember how you 
were feeling, as well as what you were thinking around the time you received your 
BRCA1 or BRCA2 results.   
 
One month after receiving your BRCA1/2 results. . . 
55a. How often were you concerned about getting breast cancer? 
 
     
 Not at all Sometimes Often A lot 
 or Rarely 
 
55b. How often did you think about your own chances of having breast cancer? 
 
     
 Not at all Sometimes Often A lot 
 or Rarely 
 
55c. How often did thoughts about breast cancer affected your mood? 
 
     
 Not at all Sometimes Often A lot 
 or Rarely 
 
55d. How often did thoughts about breast cancer affected your ability to perform your 
daily activities? 
 
     
 Not at all Sometimes Often A lot 
 or Rarely 
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Appendix J:  Decision Conflict Scale 
 
56. Think back to the time after you received your BRCA1 or BRCA2 results and were 
deciding about whether to undergo prophylactic mastectomy. Think about what 
season of the year it was. Think about the month it was. Think about the major 
holidays that occurred around this time. Most importantly, try to remember how 
you were feeling, as well as what you were thinking around the time you 
considered whether or not to undergo a prophylactic mastectomy. What did you 
think about the risk-reducing options for breast cancer (e.g., prophylactic 
mastectomy, mammography, MRI)? 
 
  
 
Strongly 
Agree 
 
 
 
Agree 
Neither 
Agree 
Or 
Disagree 
 
 
 
Disagree 
 
 
Strongly 
Disagree 
56a.  I knew which options were  
     available to me. 
 
 
 
 
 
 
 
 
 
 
56b.  I knew the benefits of each  
     option. 
 
 
 
 
 
 
 
 
 
 
56c.  I knew the risks and side effects  
     of each option. 
 
 
 
 
 
 
 
 
 
 
56d.  I was clear about which benefits  
     mattered most to me. 
 
 
 
 
 
 
 
 
 
 
56e.  I was clear about which risks and 
     side effects mattered most. 
 
 
 
 
 
 
 
 
 
 
56f.  I was clear about which was more 
    important to me (the benefits or 
    the risks and side effects). 
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Appendix J:  Decision Conflict Scale (Continued) 
 
57 How did you feel about making a decision about which risk-reducing option to 
choose? 
 
  
 
Strongly 
Agree 
 
 
 
Agree 
Neither 
Agree Or 
Disagree 
 
 
 
Disagree 
 
 
Strongly 
Disagree 
a.  I had enough support from others to 
     make a choice.  
 
 
 
 
 
 
 
 
 
 
 
b.  I chose without pressure from others. 
 
     
 
c.  I had enough advice to make a choice. 
 
     
d.  I was clear about the best choice for 
me. 
 
     
e.  I felt sure about what to choose. 
  
     
f.  This decision was easy for me to make. 
 
     
g.  I felt I made an informed choice. 
 
     
h.  My decision shows what is important 
to me. 
 
     
i.  I expect to stick with my decision. 
 
     
j.  I am satisfied with my decision. 
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Appendix K:  Decision Regret Scale 
 
58. Please reflect on the decision you have made about whether or not to undergo 
prophylactic mastectomy.  Please show how strongly you agree or disagree with 
these statements by selecting the response that best fits your views about your 
decision. 
 
 
    
 
   58a. It was the right decision..................... ρρρρρ 
 
 
   58b. I regret the choice that was made....... ρρρρρ 
 
 
   58c. I would go for the same choice if I  
 had to do it over again......................... ρρρρρ 
 
 
   58d. The choice did me a lot of harm ........ ρρρρρ 
 
 
   58e. The decision was a wise one.............. ρρρρρ 
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Appendix L:  Center for Epidemiologic Studies, Depression Scale (CES-D) 
 
For each statement below, make an X in the box which best describes how often you felt or 
behaved this way.  DURING THE PAST WEEK, INCLUDING TODAY. 
  
None of the 
Time 
A Little 
of the 
Time 
A Moderate 
Amount of 
Time 
Most of 
the 
Time 
59a. I was bothered by things that 
        usually don't bother me. 
 
ρ 
 
ρ 
 
ρ 
 
ρ 
59b. I did not feel like eating; my 
        appetite was poor. 
 
ρ 
 
ρ 
 
ρ 
 
ρ 
59c. I felt that I could not shake off     
the blues even with help from 
my family or friends. 
 
ρ 
 
ρ 
 
ρ 
 
ρ 
59d. I felt that I was just as good as 
        other people. 
 
ρ 
 
ρ 
 
ρ 
 
ρ 
59e. I had trouble keeping my mind    
on what I was doing. 
 
ρ 
 
ρ 
 
ρ 
 
ρ 
59f. I felt depressed. ρ ρ ρ ρ 
59g. I felt that everything I did was  
       an effort. 
 
ρ 
 
ρ 
 
ρ 
 
ρ 
59h.   I felt hopeful about the future.  
ρ 
 
ρ 
 
ρ 
 
ρ 
59i.   I thought my life had been a 
failure. 
 
ρ 
 
ρ 
 
ρ 
 
ρ 
59j.  I felt fearful.  
ρ 
 
ρ 
 
ρ 
 
ρ 
59k.  My sleep was restless.  
ρ 
 
ρ 
 
ρ 
 
ρ 
59l.  I was happy.  
ρ 
 
ρ 
 
ρ 
 
ρ 
59m.  I talked less than usual.  
ρ 
 
ρ 
 
ρ 
 
ρ 
59n.  I felt lonely.  
ρ 
 
ρ 
 
ρ 
 
ρ 
59o.  People were unfriendly.  
ρ 
 
ρ 
 
ρ 
 
ρ 
59p.  I enjoyed life.  
ρ 
 
ρ 
 
ρ 
 
ρ 
59q.  I had crying spells.  
ρ 
 
ρ 
 
ρ 
 
ρ 
59r.  I felt sad.  
ρ 
 
ρ 
 
ρ 
 
ρ 
59s.  I felt that people disliked me.  
ρ 
 
ρ 
 
ρ 
 
ρ 
59t.  I could not get going. ρ ρ ρ ρ 
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Appendix M:  Miller Behavioral Style Scale 
 
60. Vividly imagine that you are afraid of the dentist and have to get some dental 
work done.  Which of the following would you do?  Check all of the statements 
that might apply to you. 
 
_____  I would ask the dentist exactly what he was going to do. 
 
_____  I would take a tranquilizer or have a drink before going. 
 
_____  I would try to think about pleasant memories. 
 
_____  I would want the dentist to tell me when I would feel pain. 
 
_____  I would try to sleep. 
 
_____  I would watch all the dentists movements and listen for the sound of his drill. 
 
_____  I would watch the flow of water from my mouth to see if it contained blood. 
 
_____  I would do mental puzzles in my mind. 
 
 
 
61. Vividly imagine that you are being held hostage by a group of armed terrorists in 
a public building.  Which of the following would you do?  Check all of the 
statements that might apply to you. 
 
_____  I would sit by myself and have as many daydreams and fantasies as I could. 
 
_____  I would stay alert and try to keep myself from falling asleep. 
 
_____  I would exchange life stories with the other hostages. 
 
_____  If there was a radio present, I would stay near it and listen to the bulletins  
 what the police were doing. 
 
_____  I would watch every movement of my captors and keep an eye on their  
  weapons. 
 
_____  I would try to sleep as much as possible. 
 
_____  I would think about how nice its going to be when I get home. 
 
_____  I would make sure I knew where every possible exit was. 
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Appendix M:  Miller Behavioral Style Scale (Continued) 
 
62. Vividly imagine that, due to a large drop in sales, it is rumored that several 
people in your department at work will be laid off.  Your supervisor has turned 
in an evaluation of your work for the past year.  The decision about lay-offs has 
been made and will be announced in several days.  Check all of the statements 
that might apply to you. 
 
_____  I would talk to my fellow workers to see if they knew anything about what the 
supervisors evaluation of me said. 
_____  I would review the list of duties for my present job and try to figure out if I 
had fulfilled them all. 
_____  I would go to the movies to take my mind off things. 
_____  I would try to remember any arguments or disagreements I might have had 
with the supervisor that would have lowered his opinion of me. 
_____  I would push all thoughts of being laid off out of my mind. 
_____  I would tell my spouse that Id rather not discuss my chances of being laid off. 
_____  I would try to think which employees in my department the supervisor might 
have thought had done the worst job. 
_____  I would continue doing my work as if nothing special was happening. 
 
 
63. Vividly imagine that you are on an airplane, thirty minutes from your destination, 
when the plane unexpectedly goes into a deep dive and then suddenly levels off.  
After a short time, the pilot announces that nothing is wrong, although the rest of 
the ride may be rough.  You, however, are not convinced that all is well.  Check 
all of the statements that might apply to you. 
 
_____  I would carefully read the information provided about safety features in the 
plane and make sure I knew where the emergency exits were. 
_____  I would make small talk with the passenger beside me. 
_____  I would watch the end of the movie, even if I had seen it before. 
_____  I would call the stewardess and ask her exactly what the problem was. 
_____  I would order a drink or tranquilizer from the stewardess. 
_____  I would listen carefully to the engines for unusual noises and would watch the 
crew to see if their behavior was out of the ordinary 
_____  I would talk to the passenger beside me about what might be wrong. 
_____  I would settle down and read a book or magazine or write a letter.  
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